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ABSTRACT 
 
Protein-membrane interactions are a critical component of the coagulation cascade. For many 
coagulation factors, these interactions are mediated via γ-carboxyglutamate rich regions, or GLA 
domains, in a Ca2+-dependent manner. Nearly all studies of GLA domain-containing 
coagulation factors, and coagulation in general, have utilized supraphyisologic Ca2+ 
concentrations in order to fully occupy the 7 GLA domain metal binding sites (and thus 
maximize activity). Recent work has indicated that under physiologic conditions, 2-3 of the 
GLA domain metal binding sites are actually occupied by Mg2+; furthermore, the concentration 
of Ca2+ required to maximize coagulation factor activity is reduced to near-physiologic levels in 
the presence of physiologic concentrations of Mg2+. Together, these results suggest an important 
role for Mg2+ in coagulation. 
 To investigate the role of Mg2+ further, I first demonstrated that tissue factor is required 
for the Mg2+-dependent rate enhancements and that tissue factor itself does not bind Mg2+. To 
determine which residues of TF mediate the effect of Mg2+, I performed alanine scanning 
mutagenesis and substrate activation experiments, identifying several key residues mediating 
these effects. Importantly, these residues reside in or near the putative substrate binding exosite, 
suggesting that Mg2+ occupation of GLA domain metal binding sites may mediate both protein-
membrane and protein-protein interactions. Furthermore, in collaboration with the lab of Dr. 
Ryan Bailey in the department of analytical chemistry at UIUC, we have probed the protein-
membrane interactions of coagulation factors in a high-throughput manner utilizing photonic 
microring resonators. Additionally, we have investigated the binding of factor X to the tissue 
factor/factor VIIa complex assembled on Nanodiscs, leading to a deeper understanding of the 
effects of membrane composition and complex formation dynamics. 
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The roles of anionic polymers such as inorganic polyphosphate and nucleic acids in both 
coagulation and inflammation have recently come to light. To better understand and delineate 
their effects, I performed a head-to-head comparison of the abilities of polyphosphate, DNA, 
and RNA to activate the contact pathway of coagulation, as well as to abrogate the anticoagulant 
activity of tissue factor pathway inhibitor (TFPI). Polyphosphate was a superior contact pathway 
activator on both a weight and molar basis, and was significantly more effective in abrogating 
TFPI activity than DNA or RNA purified from biologic samples. 
 Both polyphosphate and nucleic acids are linear, anionic polymers; thus, it is possible that 
utilizing nucleic acid purification techniques on samples containing both nucleic acids and 
polyphosphate may result in co-purification of these polymers. To assess the purity of DNA or 
RNA samples purified from biological sources, I examined the co-purification characteristics of 
polyphosphate with DNA or RNA using numerous commercially-available nucleic acid 
purification techniques. Polyphosphate readily co-purified with both DNA and RNA, though to 
a significantly greater extent with the former. In addition, I demonstrated that purified cell-
derived DNA contained contaminant polyP using PAGE and staining with DAPI.  
 Because polyphosphate can co-purify with nucleic acids, investigations into the effects of 
DNA and RNA on coagulation might be indirectly probing the effects of polyphosphate 
contamination within the purified nucleic acid sample. To investigate, I treated purified cellular 
DNA with nucleases and polyphosphatases then assessed their ability to activate the contact 
pathway. Interestingly, treatment with either enzyme abrogated the procoagulant effect of 
purified DNA.  
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Though physiologic anionic polymers have recently been identified as activators of the contact 
pathway, their precise mode of action has not been elucidated. The contact pathway consists of 3 
proteolytically active enzymes, each of which have been reported to bind –and active –in the 
presence of anionic polymers. Furthermore, an important cofactor, high molecular weight 
kininogen, also binds to anionic surfaces and has been demonstrated as important for mediating 
the activities of contact pathway proteins. Nonetheless, it is often overlooked when studying the 
contact pathway in vitro. 
 To investigate the reaction-by-reaction effects of physiologic polyanions, I performed a 
series of activity assays with purified proteins of the contact pathway. These assays were run in 
the presence of polyanions, and in some experiments HK. The results demonstrate the disparate 
effects of polyanions and HK, and highlight the importance of understanding contact pathway 
activation on a per-reaction level in addition to the pathway as a whole. 
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CHAPTER 1: Introduction to the Extrinsic and Intrinsic Pathways of Coagulationa 
 
PART 1: THE EXTRINSIC PATHWAY 
Introduction 
The extrinsic tenase complex, comprised of tissue factor (TF) and factor VIIa (FVIIa), is 
a two-subunit enzyme that initiates the coagulation cascade under most in vivo conditions 
(Figure 1.1).1,2 The regulatory subunit of this complex, TF (also known as thromboplastin, 
CD142, or coagulation factor III), is a cell-surface, transmembrane protein of the class II 
cytokine receptor family that is extensively expressed amongst adventitial and epithelial tissues; 
however, tissues exposed to the vessel lumen such as endothelial cells, platelets, and leukocytes 
constitutively express little or no TF.3-5 The enzymatic subunit is a plasma protein, FVIIa, that is 
a trypsin-like serine protease demonstrating homology with several other coagulation proteins, 
including its cognate substrates factors IX (FIX) and X (FX). Total FVII (active enzyme and 
zymogen) circulates in plasma at a concentration of approximately 10 nM; however, only about 
1% is in the active form.6 Due to its poor enzymatic activity, free FVIIa in plasma largely escapes 
recognition by protease inhibitors and therefore circulates with a half-life of ~90 minutes.7,8 The 
extended half-life afforded to FVIIa may serve an important function, as low basal 
concentrations of pre-formed FVIIa may serve to “prime” the coagulation cascade for a rapid 
response to injury.6  
																																																						
a Part 1 of this chapter has been adapted in its entirety from a review article originally published online in the journal Seminars in 
Thrombosis and Hemostasis, and used in accordance with the publisher’s copyright privileges for publication in a dissertation thesis. Full 
Citation: J. M. Gajsiewicz and J. H. Morrissey (2015). "Structure-Function Relationship of the Interaction between Tissue Factor and 
Factor VIIa." Seminars in Thrombosis and Hemostasis 41(7): 682-690. 
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Under homeostatic conditions, TF and blood are physically separated, but vascular injury 
exposes plasma (which contains FVII and FVIIa) to a variety of TF-expressing cells. Once 
zymogen FVII binds to TF, it is rapidly converted to FVIIa by limited proteolysis, thereby 
generating the active TF-FVIIa complex. Formation of the TF-FVIIa complex greatly increases 
the enzymatic activity of FVIIa via allosteric interactions between TF and FVIIa, as revealed by 
about a 20- to 100-fold increase in the rate of hydrolysis of small, chromogenic peptidyl 
substrates (termed its amidolytic activity),9,10 and nearly a million-fold increase in the rate of 
activation of the macromolecular substrates, FIX and FX.11 Subsequently FIXa, in association 
with its regulatory subunit FVIIIa, further activates FX; FXa in turn complexes with its cofactor 
FVa, to proteolytically cleave prothrombin to thrombin, leading to fibrin clot formation. 
Widespread, constitutive expression of TF on cells surrounding organs, blood vessels, and skin 
serves to create a “hemostatic envelope” that initiates clotting upon vascular injury.3  
 An additional point of modulation of TF-FVIIa is via the phospholipid bilayer. In 
concert with allosteric activation of the active site of FVIIa upon binding to TF, formation of the 
extrinsic tenase on a suitably procoagulant phospholipid bilayer increases the rate of FIX or FX 
activation, in a Ca2+-dependent manner, an additional 1,000-fold.11 In fact, nearly all reactions of 
the coagulation cascade are reliant upon exposure of phosphatidyl-L-serine (PS) on membrane 
surfaces.12 The roughly million-fold overall increase in FX activation by the TF-FVIIa-
phospholipid complex relative to free FVIIa is critical regulatory point for the coagulation 
cascade.13 The roles of TF-FVIIa in hemostasis, thrombosis and other biological processes are 
numerous, and the structural underpinnings comprising the foundation of their activities 
continue to be a point of focus and investigation. 
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Structure 
Tissue Factor 
 TF, a 263 amino acid glycoprotein with a molecular weight of ~46kDa and member of 
the cytokine class II receptor family, is composed of three domains: a 219 amino acid N-terminal 
extracellular domain (residues 1-219); a 22 amino acid transmembrane domain (residues 220-
242); and a 21 amino acid cytoplasmic C-terminal tail (residues 242-263). The cytoplasmic tail 
contains two phosphorylation sites at Ser253 and Ser258, and one S-palmitoylation site at Cys245. 
Removal of the cytoplasmic domain has no deleterious effects on TF coagulant activity. The TF 
transmembrane domain is composed of a single-spanning alpha-helix, the precise identity of 
which has been shown unimportant for TF procoagulant function;14 anchoring of a histidine-
tagged extracellular domain of TF to the membrane using nickel-chelating lipids resulted in full 
restoration of procoagulant activity of TF.15 The extracellular domain of TF (sTF) is composed 
of two fibronectin type III domains, and is connected to the transmembrane domain through a 
six-amino acid linker. This linker likely exhibits sufficient flexibility to conformationally 
decouple the extracellular domain of TF from the transmembrane and cytoplasmic domains.14,16 
The fibronectin type III domain structure, composed mainly of beta-strands connected by β-
loops, is a member of the immunoglobulin-like family of protein folds and is conserved amongst 
a wide variety of extracellular proteins.17 
The procoagulant activity of TF does not necessarily correlate with its levels of cell-
surface expression. Much of the TF expressed on a cell surface is ‘encrypted’, and must first be 
‘decrypted’ to participate fully in coagulation reactions. The process by which this occurs has yet 
to be fully explained, and is likely a combination of several mechanisms. One clear contributor is 
exposure of anionic phospholipids. Healthy cells actively sequester anionic phospholipids such as 
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PS to the inner leaflet of the plasma membrane,18,19 but following cellular damage, activation, or 
increased levels of cytosolic Ca2+ this bilayer asymmetry is lost, resulting in increased PS exposure 
on the outer leaflet which increases the specific activity of cell-surface TF-FVIIa complexes. PS 
exposure is well known to decrease the apparent Km for activation of FIX and FX, but additional 
mechanisms could include conformational rearrangement of TF or the TF-FVIIa complex and 
subsequent exposure of substrate binding sites.16,20 Expression levels of GRP78, a molecular 
chaperone protein, have also been shown to mediate TF procoagulant activity in a Ca2+-
dependent manner and thus may also play a role in its decryption.21,22 
A fascinating suggestion is that disulfide linkages play a role in TF 
encryption/decryption, and in particular, that the membrane-proximal cysteine pair in TF 
(Cys186-Cys209) is an 'allosteric' disulfide that is subject to redox control, leading to TF 
encryption/decryption.23-25 Others have disputed this conclusion, however, and have proposed 
alternative explanations for the observed effects (reviewed in 26,27). Though the importance of TF 
disulfide bond formation towards its cofactor activity has yet to be resolved, FVIIa binding to TF 
is not dependent on the oxidation state of Cys186 and Cys209.23 A number of insightful and 
detailed reviews focus on controversies surrounding TF decryption are available.28-32 
 
Factor VII/VIIa 
 The trypsin-like serine protease FVII (in the inactive precursor, or zymogen form) is a 
~50KDa, single-chain polypeptide consisting of 406 residues, with an N-terminal γ-
carboxyglutamate-rich (GLA) domain, two epidermal growth factor-like domains (EGF1 and 
EGF2), and a C-terminal serine protease domain.33-36 Activation of FVII to FVIIa is 
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accomplished via specific proteolytic cleavage of the Ile153 -Arg152 bond in the short linker region 
between the EGF2 and protease domain, with the resultant light and heavy chains held together 
by a single disulfide bond (Cys135-Cys262). FVII has significant structural and sequence homology 
to coagulation factors IX, X, and protein C.37,38  
 FVIIa binds the phospholipid membrane in a Ca2+-dependent manner through its N-
terminal GLA-domain. Containing 10 vitamin K-dependent, posttranslationally modified γ-
carboxyglutamate (Gla) residues, GLA-domains coordinate 7-9 divalent metal ions such as Ca2+ 
and Mg2+, inducing conformational rearrangements that are requisite for interaction with 
membrane surfaces.39,40 
 Immediately C-terminal to the GLA domain is an aromatic stack and two epidermal 
growth factor (EGF) domains (EGF1 and EGF2). The aromatic stack connects the GLA to 
EGF1 domain, which binds a single Ca2+ ion with moderately high affinity.41,42 Occupancy of 
this Ca2+-binding site increases FVIIa amidolytic activity and TF association.43 The FVIIa heavy 
chain comprises the trypsin-like protease domain, which is also homologous to other coagulation 
serine proteases such as FX, FIX, protein C, and prothrombin. The catalytic triad consists of 
His193, Asp242 and Ser344, and binding of a single Ca2+ ion within the FVIIa protease domain is 
critical for catalytic activity.41,44 Additionally, proteolytic activation of FVII to FVIIa frees the 
newly formed amino terminus at Ile153 to fold back and insert into the activation pocket, forming 
a salt bridge with the carboxylate of Asp343 to generate the oxyanion hole.45 Formation of this salt 
bridge is critical for FVIIa activity; indeed, FVIIa with the mutation V154G is cleaved to the 
two-chain form normally and with wild-type macromolecular substrate affinity,46 but with 
significantly reduced ability of the resultant FVIIa to activate FX.46,47 Reduced N-terminal 
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hydrogen-deuterium exchange upon TF binding to FVIIa supports the hypothesis that the N-
terminal Ile153 is not fully inserted into the activation pocket when free in solution.48 
Additionally, unlike most other serine proteases, oxyanion hole formation in free FVIIa does not 
occur upon proteolytic activation, but instead upon substrate interaction.49 As a result, FVIIa 
circulates in a zymogen-like state that is poorly recognized by plasma protease inhibitors,49 
allowing it to circulate with a half-life of approximately 90 minutes.7,8 This is far longer than 
other coagulation enzymes such as FIXa, FXa and thrombin, whose plasma half-lives are on the 
order of seconds to minutes.50,51 
 
Structure-Function Relationship 
Association of TF with FVIIa allosterically activates the protease, creating what is 
essentially a dimeric enzyme in which TF is the regulatory subunit and FVIIa the catalytic 
subunit. The ability to cleave very small, tripeptidyl-amide substrates (amidolytic activity) of 
FVIIa is increased approximately 50-fold upon binding of TF, with the largest change being 
increased kcat,9,10 indicating that TF association induces conformational changes within the active 
site of the FVIIa protease domain.45,52-54 Additionally, pKa values of the catalytic triad are altered 
upon TF binding.55 It has been hypothesized that FVIIa in solution exists in an equilibrium 
between two states; one in which the heavy-chain N-terminus has inserted into the active site 
pocket, and one that is more zymogen-like with the N-terminus incorrectly or incompletely 
inserted. TF may preferentially bind FVIIa when it is in the catalytically active form,45 shifting 
the equilibrium towards the active (N-terminal buried) conformation. Hydrogen-deuterium 
exchange experiments coupled with mass spectrometry have demonstrated that several loop 
regions within the protease domain of FVIIa are stabilized upon binding to TF, through 
	 7	
rearrangement and strengthening of an extensive hydrogen bonding network.48,52 These 
structural changes are not limited to the protease domain but extend throughout most of 
FVIIa,48 indicating widespread allosteric modulation of FVIIa by TF. 
 
Active Site Positioning 
In vivo enzymatic activity of the TF-FVIIa complex occurs exclusively on the 
phospholipid membrane surface, and is dependent upon the interaction of FVIIa, FIX and FX 
with the membrane through their membrane-binding GLA-domains. Fluorescence resonance 
energy transfer (FRET) experiments indicate that free FVIIa adopts a stable, extended structure 
when bound to the membrane, with its active site positioned ~80 Å above the membrane 
surface.56 This distance is in good agreement with those seen for the homologous proteins FIXa57 
and FXa58. Upon FVIIa binding to TF, the FVIIa active site is repositioned ~6 Å closer to the 
membrane, a modulation that may aid in proper alignment of the FVIIa catalytic triad with the 
target substrate cleavage site.56 In comparable FRET experiments using GLA-domainless FVIIa, 
the active site was still positioned a similar distance above the membrane, demonstrating that TF 
is able to fully support FVIIa active site positioning even in the absence of FVIIa-membrane 
interactions.59 Further, experiments using multiple approaches have shown that TF supports full 
FVIIa proteolytic activity as long as the TF extracellular domain is tethered in some way to the 
membrane surface, while the exact nature of this membrane tether is essentially irrelevant.14,15,60 
In contrast, raising the active site of FVIIa greater than 80 Å above the membrane surface using 
TF/P-selectin chimeras greatly reduced the ability of the TF-FVIIa complex to activate FX, but 
did not diminish TF-FVIIa amidolytic activity. This indicates that TF-mediated positioning of 
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the FVIIa active site above the membrane surface is important for its activity towards cognate 
substrates.61 
Molecular dynamics (MD) simulations of TF-FVIIa in the presence of membrane 
surfaces indicate TF reduces FVIIa flexibility. Intra-domain dynamics (Cα RMSD) are small 
compared to inter-domain flexibility, suggesting TF interaction significantly rigidifies FVIIa 
domains relative to each other.16 
 
Spatial Stabilization 
Free FVIIa is an inherently dynamic molecule, with MD simulations, fluorescence 
anisotropy, and hydrogen-deuterium exchange data indicating intra- and inter- domain 
flexibility.16,52,62-64 A major component of TF allosteric modulation of FVIIa activity is the 
stabilization and reduced flexibility of FVIIa upon TF binding. In the protease domain, 
stabilization of the 170-loop located near the TF interaction site appears to be important for 
FVIIa amidolytic activity.63,64 Replacement of the loop with that of a similar but truncated loop 
from trypsin results in an increase in FVIIa amidolytic activity even in the absence of TF, 
suggesting that stabilization of the 170-loop plays a significant role in TF-mediated allosteric 
activation of FVIIa.65 Additionally, hydrogen exchange experiments and MD simulations show 
that TF binding aids the insertion of Ile153 into the activation pocket of FVIIa and stabilizes its 
structure, even after removal of the N-terminal insertion.52,63 Specific TF and FVIIa residues 
have been identified that contribute to stabilization of FVIIa within the TF-FVIIa complex. 
Alanine scanning mutagenesis studies66 and crystallography data41 demonstrated that Met306 in 
FVIIa plays a pivotal role in TF interactions, restricting the flexibility of FVIIa’s 170-loop upon 
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FVIIa-TF complex formation. The crystal structure of free FVIIa,67 in which the 170-loop and 
precluding α-helix (containing Met306) are more disordered, also supports this idea. 
 
TF-Substrate Interactions 
In addition to the role of TF in allosterically activating FVIIa, binding interactions 
between the ‘exosite’ region of TF and macromolecular substrates are also implicated in TF-
FVIIa catalytic activity. The known physiologic substrates of TF-FVIIa are FVII, FIX, FX and 
certain protease activated receptors (PARs). TF mutational analysis has identified a number of 
residues that, when mutated, support full FVIIa amidolytic activity towards small peptidyl 
substrates but are deficient in their ability to support macromolecular substrate (FVII, FIX, FX) 
activation.68-70 Several crystal structures have shown disorder in the TF loop region at residues 
159-165,41,49 and residues in or adjacent to this flexible loop have been shown to be especially 
critical for proteolytic activity of the TF-FVIIa complex, thereby defining the proposed 
substrate-binding exosite region of TF that is quite distant from the FVIIa active site.68,69 
Interestingly, mutation of Gly164 of TF to a marginally more bulky alanine significantly impairs 
TF-FVIIa proteolytic activity, suggesting the flexibility afforded by glycine is critical for 
macromolecular substrate recognition.68,70 
 TF residues Lys165 and Lys166 have also been demonstrated to be important for substrate 
recognition and binding; mutation of either of these residues to alanine results in a significant 
decrease in the cofactor function of TF.68,69,71,72 However, TF with mutations at K165A and 
K166A activated GLA-domainless FX at rates comparable to that of the wild-type TF, and 
utilization of GLA-domainless FVIIa greatly muted the effects of these TF mutations on FX 
activation.69 Crystal structures have indicated that Lys165 and Lys166 face away from each other, 
	 10	
with Lys165 pointing towards FVIIa in most TF-FVIIa structures, and Lys166 pointing into the 
substrate binding exosite region.41,73 Putative salt bridge formation between Lys165 of TF and 
Gla35 of FVIIa would support the notion that TF interaction with the GLA-domain of FVIIa 
modulate substrate recognition.73 Taken together, these results suggest that the C-terminal 
portion of the TF ectodomain directly interacts with the GLA-domains (and possibly the 
adjacent EGF1 domains) of FIX and FX, and that the presence of the FVIIa GLA-domain may 
modulate these interactions, either directly or indirectly. Furthermore, the TF residues involved 
in substrate interactions with FIX and FX are similar or identical to those that interact with FVII 
during TF-mediated FVII autoactivation,53 indicating a similar mechanism of substrate binding. 
A number of monoclonal anti-TF antibodies have been raised, with the vast majority 
blocking association between TF and FVII.74 However, two monoclonal antibodies, TF8-5G9 
and TF8-11D12 (which came from the same fusion and which are probably identical) were 
shown not to inhibit TF-FVIIa binding, but to strongly inhibit activation of FIX and FX by TF-
FVIIa.75,76 Crystal structures of TF in complex with the antibody TF-5G977 indicates that the 
epitope on TF for this antibody overlaps significantly with the substrate interaction (exosites) 
region identified by Kirchhofer et al.70 More recently, two additional monoclonal anti-TF 
antibodies (D3 and 5G6) with similar properties have also been reported.78 
Monoclonal antibody TF9-10H10 binds to TF but does not inhibit its procoagulant 
activity, which is unusual as almost all anti-TF antibodies are inhibitory.74 More recent studies 
using this antibody have shown that it does inhibit the ability of the TF-FVIIa complex to 
participate in signaling.79 These results suggest that TF-FVIIa signaling via integrins and PAR-2 
is mediated by exosite-like interactions on TF distinct from those involved in TF-FVIIa 
procoagulant functions. 
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Protein-Membrane Interactions 
 Lipid bilayer composition plays an important role in activity of the TF-FVIIa complex. 
GLA-domain containing coagulation proteins are well-known to preferentially bind anionic 
phospholipids in general, and PS in particular.12 PS is, however, actively sequestered to the inner 
leaflet of the plasma membrane, serving as an important point of regulation of blood 
clotting.12,18,19,80 Exposure of PS on the outer leaflet occurs either via physical disruption of the 
cell membrane as a consequence trauma, or via regulated cellular processes such as those that 
occur upon platelet activation. Interestingly, despite the high degree of sequence homology 
between GLA-domains of different clotting proteins, their membrane binding affinities vary by 
three orders of magnitude,81,82 with FVIIa and activated protein C (APC) displaying the weakest 
affinities for PS-containing bilayers. We recently reported that FVIIa and APC preferentially 
bind to bilayers containing phosphatidic acid (PA), a minor anionic lipid in cell membranes.83 
PA has minimal effect on TF-FVIIa activity in vitro, however, likely due to the fact that protein-
protein interactions between TF-FVIIa dominate the recruitment of FVIIa to the membrane.84 
Further, when used pharmacologically to treat bleeding disorders, the mechanism of action of 
recombinant FVIIa has been shown to be independent of TF.85,86 Thus, the membrane binding 
characteristics of “free” (non-TF bound) FVIIa may be an important component of its in vivo 
efficacy, especially when high concentrations of recombinant FVIIa are employed to treat 
bleeding. 
 Direct interactions between the TF ectodomain and the membrane surface may also 
contribute to the activity of the TF-FVIIa complex. It is thought that there is considerable 
freedom of motion and autonomy of the TF ectodomain relative to the membrane due to the 
	 12	
structural flexibility of the short peptide linker between the ectodomain and the transmembrane 
domain.14 Furthermore, MD simulations have identified a number of TF residues in the C-
terminal portion of the ectodomain that directly contact the phospholipid membrane surface. 
These residues maintained association of sTF (i.e., the isolated ectodomain) with the membrane 
surface, suggesting that TF residues may associate directly with PS headgroups.16 Additionally, 
simulations suggest the orientation of TF with respect to the membrane is altered upon FVIIa 
binding, with TF leaning toward FVIIa. As a result, the TF residues in contact with the 
phospholipid membrane are proposed to change.16 This region of putative membrane-interacting 
TF residues is immediately adjacent to the proposed substrate-binding exosite, and alanine 
scanning mutagenesis studies have identified mutations in this region that alter the ability of 
membrane-anchored TF-FVIIa to activate FX.20 Interestingly, increasing the PS content of TF-
liposomes partially overcomes these deficiencies, suggesting that direct PS-TF interactions may 
either stabilize the complex or induce ideal conformational arrangements, promoting interaction 
of FIX and FX with the TF exosite.16,20 
 Biochemical studies of protein-membrane interactions in blood clotting often utilize 
liposomes with non-physiological membrane compositions. Thus, it typically requires 30% or 
more PS to achieve maximal TF-FVIIa enzymatic activity in vitro,87 while only ~10% of the total 
plasma membrane bilayer is composed PS in eukaryotic cells.88  Incorporation of 
phosphatidylethanolamine (PE, a plasma membrane phospholipid that is much more abundant 
than PS) into TF-liposomes markedly decreases the required PS content, although PE by itself 
does little to promote TF activity.87 Other lipids such as phosphatidic acid, phosphatidylglycerol, 
and phosphatidylinositol also reduce the PS requirement, indicating ‘synergy’ between PS and 
PE is not a unique property of PE but a more broadly encompassing mechanism. This ‘ABC 
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hypothesis’ (Anything But Choline) postulates that any lipid not containing the bulky choline 
headgroup of PC or sphingomyelin can ‘synergize’ with PS and decrease the required PS content 
for maximal enzymatic activity.  
 
Divalent Metal Ions 
 Calcium ions are required for assembly and function of TF-FVIIa. Although TF lacks 
any known divalent metal ion binding-sites, Ca2+ can occupy up to nine metal binding sites 
within FVIIa. Of these, seven reside in the GLA-domain of FVIIa and are critical for both 
structure and function of this domain. In particular, Gla7 and Gla9 coordination of Ca2+ induces 
formation of the ω-loop, which exposes hydrophobic residues that are believed to insert into the 
bilayer.87,89-91 Recent crystallographic, enzymatic, and equilibrium dialysis studies have indicated 
that the FVIIa GLA-domain actually binds a combination of 4-5 Ca2+ and 2-3 Mg2+ under 
physiologic divalent metal ion conditions.49,73 Ca2+ is absolutely required for GLA-domain 
structure and function, and can occupy all GLA-domain metal binding sites when it is the only 
divalent metal ion present (especially at supraphysiologic concentrations of Ca2+), but Mg2+ alone 
is unable to induce the correct GLA-domain structure. This suggests that a subset of metal 
binding sites in GLA domains are occupied with Mg2+ in vivo,40,73 and occupancy of these sites 
by Mg2+ even in the presence of vast excesses of Ca2+ suggest these sites preferentially bind Mg2+ 
in plasma.49,73 The reasons for differential metal ion specificity of GLA domains remain unclear, 
but are likely due to differences in coordination geometries of each binding site along with the 
‘hardness’ properties of Ca2+ versus Mg2+.73,92 Mg2+ has been demonstrated to modulate both the 
membrane binding73 and enzymatic properties93 of FVIIa and FIX94.  
	 14	
One Ca2+ binds to the EGF1 domain of FVIIa, for which Mg2+ cannot substitute. 49 This 
Ca2+ is implicated in optimizing TF-FVIIa binding interactions, likely through modulating the 
orientation of the FVIIa GLA-domain relative to the EGF1 domain.95 The protease domain of 
FVIIa also contains one Ca2+ binding site; its occupancy results in allosteric activation through 
reregistration of the Ca2+ binding loop.52 Additionally, two Zn2+ binding sites have been 
identified in the protease domain, although Zn2+ occupancy of these sites inhibits both FVIIa 
enzymatic activity and TF binding.49,96 
 The Ca2+ binding sites in FVIIa are incompletely saturated at plasma concentrations of 
free Ca2+ (~1.25 mM).97,98 However, using the plasma concentrations of free Ca2+ and Mg2+ 
(~1.25 mM and ~0.6 mM, respectively) restores activity to maximal levels, indicating that Mg2+ 
likely plays a role in vivo.73,93,94,99 The GLA-domains of both FVIIa and FX mediate enzymatic 
rate enhancements due to Mg2+, suggesting that conformational changes of the FX GLA-
domain upon Mg2+ occupancy of metal binding sites modifies its interactions with TF.99 
  
Signaling 
The role of TF in cellular signaling is incompletely understood, though it is known to 
play roles in tumor growth,79 metastasis,100,101 angiogenesis, and anti-apoptotic signaling;102 
additionally, TF is known to be upregulated in many malignant tumor cell types.103-105 FVIIa 
binding to TF has been implicated in directly mediating PAR-2 cleavage via mechanisms both 
dependent106-109 and independent110,111 of the cytoplasmic domain of TF.112 Phosphorylation of 
the TF cytoplasmic domain subsequent to TF-FVIIa cleavage of PAR-2 is thought to release 
TF-dependent negative regulation of PAR-2 mediated signaling.79,103,108 This results in mitogen-
activated protein kinase (MAPK) pathway activation and downstream effects, including the 
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upregulation of cytokines and proangiogenic factors.103,113 Activation of the p44/42 MAPK 
pathway, as well as JAK2, p70/p85S6K, and p90RSK, can occur independent of the TF cytoplasmic 
domain.110,114,115 Though the cytoplasmic domain is not necessary for activation of these proteins, 
proteolytically active FVIIa is required. In addition, TF can also mediate signaling through the 
enzymatic activity of FXa in complex with TF-FVIIa, which plays an important role in the 
regulation of several pathways. TF-FVIIa-FXa-mediated cleavage of PARs, particularly PAR-2, 
has been shown to up-regulate IL-8 expression, resulting in increased cell migration.101 A 
number of detailed reviews can be found regarding TF-FVIIa-mediated signaling.101,103,116,117 
 
Conclusion 
The interaction between TF and FVIIa is a critical component of hemostasis. TF is 
expressed extensively on cells outside the vasculature, creating a ‘hemostatic envelope.’ 
Disruption of the blood vessel endothelium results in exposure of blood coagulation proteins, 
including FVIIa, to TF-bearing cells. Subsequent to TF-FVIIa complex formation, two blood 
clotting zymogens, FIX and FX, are proteolytically activated, propagating the coagulation 
cascade and resulting in fibrin deposition and clot formation. The physical separation of TF from 
the plasma clotting enzymes is undoubtedly a regulatory mechanism; without its protein cofactor, 
FVIIa is a very weak enzyme and will not initiate coagulation at physiologic concentrations. 
Expression of TF inside the vasculature results in aberrant coagulation cascade activity and is 
believed to play an important role in many thrombotic disorders.  
 TF modulates FVIIa activity through a number of mechanisms. FVIIa interaction with 
TF has been demonstrated to position its active site ~75 Å above the membrane surface, ~6 Å 
closer than FVIIa in the absence of TF. Additionally, MD simulations have suggested that TF 
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restricts both FVIIa inter- and intra- domain flexibility, particularly within the protease domain. 
TF has been shown to stabilize a number of loop regions in the protease domain of FVIIa as well 
as facilitate the insertion of the N-terminus of the FVIIa heavy chain into the activation pocket, 
which is critical for its enzymatic activity. In addition, an extended substrate binding exosite has 
been identified on TF, which has been shown to interact directly with both extrinsic tenase 
complex substrates, FIX and FX. The importance of the phospholipid membrane in mediating 
the activity of TF-FVIIa cannot be understated; recruitment of FX to the membrane surface is 
dependent upon the exposure of anionic phospholipids, particularly PS, which may interact with 
substrates (FIX and FX), enzyme (FVIIa) and protein cofactor (TF). All the interactions 
between TF, FVIIa, protein substrates and membrane surfaces are dependent upon divalent 
cations. Although several structures of TF-FVIIa have been solved, as of yet no tertiary TF-
FVIIa-FX or TF-FVIIa-FIX structures have been determined, nor has the role of the membrane 
surface in the formation of these complexes been determined structurally. Such results would 
provide significant information regarding the structure-function relationship of the extrinsic 
tenase in blood clotting. 
 
PART 2: THE INTRINSIC PATHWAY 
Introduction 
 The intrinsic, or contact, pathway of coagulation begins with the autoactivation of factor 
XII (FXII) to FXIIa upon interaction with anionic surfaces.118,119 FXIIa cleavage of plasma 
prekallikrein (PPK) to plasma kallikrein (PK) creates a positive activation feedback loop,120 
leading to further FXII activation by PK and high-molecular weight kininogen (HK). The 
cleavage of HK by PK releases bradykinin, a potent vasodilator and proinflammatory 
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peptide.121,122 After activation, FXIIa cleaves factor XI (FXI); subsequently, factor IX (FIX) is 
activated via limited proteolysis by FXIa. The newly generated FIXa then activates factor X (FX) 
in the presence of factor VIIIa (FVIIIa), initiating downstream proteolysis within the common 
pathway and clot formation. Figure 1.1 depicts both the extrinsic, intrinsic, and common 
pathways of coagulation.  
 For years the primary functions of the contact pathway in vivo appeared to be the release 
of bradykinin; the physiologic importance of the contact pathway to blood coagulation was 
unknown. Patients deficient in FXII demonstrate no bleeding phenotype, and mouse models 
support these observations.123 Furthermore, the contact pathway has been traditionally activated 
upon contact of blood plasma with non-physiologic, anionic surfaces such as glass, diatomaceous 
earth, or kaolin;124 thus, it was unclear what, if any, physiologic substances activated the pathway. 
However, recent work has identified a number of possible physiologic activators of FXII. 
Interestingly, the contact pathway appears to be dispensable for normal hemostasis but play 
important roles in thrombosis. Animal models suggest that FXII deficiency is 
thromboprotective,121,125 and numerous other investigations indicate a correlation between 
atherosclerosis or heart attack and elevated plasma protein levels of FXII, FXI, or PK.126-129 In 
addition to releasing bradykinin and initiating the contact pathway of coagulation, FXII has been 
demonstrated to modulate fibrinolysis and platelet function.123 Thus, the roles of the contact 
pathway are numerous and inextricably link coagulation and inflammation. 
 
Structure and Function 
FXII(a) 
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 FXII, a 596 amino acid glycoprotein with a molecular weight of ~80 kDa, is synthesized 
in the liver and circulates in blood at a concentration of about 375 nM.123 The light and heavy 
chains contain 243 and 353 residues, respectively, and are held together by a single disulfide 
bond. The heavy chain contains 6 domains and is thought to mediate the interactions of FXII 
with negatively charged surfaces, while the light chain contains the active site. The activation of 
FXII can occur via limited proteolysis by PK119,130 and by autoactivation, initiated by FXII 
interaction with anionic surfaces and subsequent conformational changes.131-134 It is believed that 
FXII binding to anionic surfaces is mediated through its type II fibronectin domain, second 
EGF domain, and kringle domain.135-139 The cognate substrates for FXIIa are PPK and FXI; 
importantly, FXII is known to exist in two forms, α-FXIIa and β-FXIIa. α-FXIIa is full length 
and fully active against PK and FXI, while β-FXIIa has been cleaved a second time, releasing a 
28 kDa protein that is no longer able to activate FXI or bind anionic surfaces, but retains its full 
activity against PPK.140 Recent work suggests that FXIIa can mediate coagulation independent of 
FXI in the presence of polyP, suggesting alternative substrates exist downstream of FXI in the 
coagulation cascade.141 FXII deficiency is not associated with bleeding in humans;142 FXII-
deficient mice also demonstrate normal hemostasis,143,144 albeit with slightly impaired thrombus 
stabilization.145,146 
  
PPK/PK  
 PPK, also made in the liver, is a 609 amino acid glycoprotein with varying degrees of 
glycosylation, leading to molecular weights of 85 kDa or 88 kDa.147 PPK circulates in plasma at a 
concentration of ~500 nM, 75% of which is bound to HK,147 and is activated to PK via cleavage 
by FXIIa and HK into a 248 amino acid light chain and 371 amino acid heavy chain; PPK can 
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also undergo autoactivation in the presence of anionic polymers.148 Creating a positive feedback 
loop, PK and its cofactor HK reciprocally activate FXII. The cognate substrates for PK are FXII 
and HK.121 PPK deficiency is not associated with bleeding in humans. 
 
HK 
 HK, a 110 kDa plasma protein, circulates at a concentration of ~640 nM. HK serves as a 
cofactor for both FXII activation by PK and for PPK activation by FXIIa, and is required for PK 
formation via surface activation.123,149 PK cleavage of HK results in release of bradykinin from 
HK, leading to propagation of the kallikrein-kinin pathway.121 In addition to circulating in 
complex with PPK, HK also circulates in complex with FXI,150 and acts to indirectly anchor both 
FXI and PPK to the membrane surface through its own interactions with proteoglycans and 
heparan.151 Deficiencies in HK are not associated with bleeding. 
 
FXI(a) 
 FXI, with a monomer molecular weight of 80 kDa, circulates as a homodimer in plasma 
at a concentration of ~30 nM. Activation of FXI occurs via limited proteolysis by FXIIa in the 
presence of Ca2+ and HK, or it can occur via autoactivation (i.e., FXI activation by FXIa);152-154 
additionally, FXI can be activated by thrombin in the presence of negatively charged surfaces,155 
particularly polyphosphate (polyP).156 Once activated, FXIa activates FIX in a Ca2+-dependent 
manner, leading to FX activation and subsequent clot formation. Deficiency in FXI results in a 
mild bleeding disorder, termed hemophilia C, which presents most often in tissues high in 
fibrinolytic activity after trauma or surgery.157-161  
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C1 Esterase Inhibitor 
 C1-Inhibitor is a 104 kDa member of the serpin superfamily, and is the main inhibitor 
responsible for regulating the contact and complement pathways. As an acute-phase protein its 
concentration can increase greatly during inflammation from its basal circulating concentration 
of ~1.8 µM.162 C1-Inhibitor is a key regulator of FXIIa, PK, and FXIa; deficiency in C1-
Inhibitor results in hereditary angioedema, a disorder resulting from the increased plasma PK 
concentration and subsequent bradykinin release.  
 
Contact Pathway Activators  
In vitro 
 A number of artificial anionic surfaces are known contact pathway activators; indeed, 
these substances have been used for years as the activators in the clinical aPTT assay, used to 
probe the contact and common pathways of coagulation, as well as monitor patients being 
treated with anticoagulants such as heparin. A shared property of most of these substances 
responsible for contact pathway activation is their polyanionic nature, which is thought to 
mediate FXII autoactivation, and subsequent reciprocal activation of FXII by PK and HK. One 
notable example is glass, as the clotting of blood collected into glass tubes in the absence of metal 
chelators can be attributed to glass-mediated contact pathway activation. In addition, kaolin, 
dextran sulfate, and diatomaceous earth are all activators of the contact pathway.163,164  
 
In vivo 
 For decades the physiologic activators of the contact pathway in vivo were unknown. 
Recently, renewed interest in the (patho)physiology of the contact pathway has led to the 
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identification of numerous candidate in vivo activators, including DNA,165-167 RNA,166,167 
misfolded proteins,168 and polyP.169,170 These activators will be discussed in greater detail in the 
following sections. 
 
Misfolded protein 
 A number of studies have identified misfolded proteins as potential activators of FXII. 
Aggregated amyloid β peptide, believed to be play a role in Alzheimer’s disease, has been shown 
to activate FXII in vivo.171 Misfolded protein aggregates also activate FXII, leading to the 
production of PK;168 interestingly, these aggregates did not result in the generation of FXIa, 
suggesting differential regulation of the contact pathway of coagulation and the kallikrein-kinin 
pathway. Furthermore, misfolded protein interactions with FXII are mediated through the 
fibronectin type I domain of FXII,172 distinct from its anionic surface binding domains. 
 
Nucleic Acids 
 Nucleic acids are released from cells into the extracellular space following a number of 
events, including apoptosis and extrusion; neutrophils have been shown to release their nuclear 
content –termed neutrophil extracellular traps, or NETs– under certain conditions, a process 
known as NET-osis.173 A number of studies have identified extracellular nucleic acids as 
potential in vivo activators of the contact pathway.166,174,175 Kannemeier et al166 provided both in 
vitro and in vivo evidence for the activation of contact proteins by extracellular nucleic acids, and 
demonstrated that FXII and FXI bound cell-derived RNA tightly while PPK and HK bound 
more weakly. Investigations into the possible role of nucleic acid structure towards its 
procoagulant ability suggest that secondary structure is an important consideration.176 
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Additionally, extracellular DNA purified from cellular sources has been shown to modulate clot 
structure and mediate fibrinolysis.177 Recent work from our lab has indicated that the 
procoagulant effects of cell-free nucleic acids may be due, in part, to the presence of contaminant 
polyP that co-purifies readily with DNA or RNA.  
 
PolyP 
 PolyP is a linear anionic polymer of phosphate molecules, held together by high-energy 
phosphoanhydride bonds, and can be tens to thousands of phosphate residues long.178 PolyP is an 
ancient molecule and can be found across all branches of life.179,180 Microorganisms synthesize 
and store very long-chain polyP, up to thousands of units in length, in granules known as 
acidocalcisomes.181-183 In these subcellular compartments, polyP is often in complex with metal 
ions under acidic conditions, and is hypothesized to play important roles in metal and energy 
storage.184,185 Mammalian cells, such as platelets, store much shorter polyP –60 to 100 units long– 
in dense granules; these granules are evolutionarily related to acidocalcisomes in 
microorganisms.186,187 PolyP has also been found in mast cell granules,187 lysosomes,188 
mitochondria, nuclei, and across numerous tissue types spanning heart, lung, brain, and 
kidneys.189 
 PolyP is a potent activator of the contact pathway of coagulation, promoting the 
activation of FXII and the kallikrein-kinin pathway. PolyP-mediated activation of FXII appears 
to occur via an allosteric activation mechanism, as proteolytically active single-chain FXII is 
generated in the presence of polyP. Upon disruption of the polyP-FXII interaction, the enzyme 
returns to its inactive, zymogen state.133 PolyP binds with high affinity to numerous proteins of 
the coagulation cascade, and contact pathway in particular.190-192 
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 Interestingly, the effects of polyP are dependent upon the polymer length.190 Short-chain 
polyP, such as that found in and secreted from platelet dense granules, weakly activates the 
contact pathway but strongly supports Factor V activation and back-activation of FXI by 
thrombin.156,190,191 Conversely, long-chain polyP, up to thousands of phosphate monomers in 
length, potently activates the contact pathway, supports factor V activation, accelerates thrombin 
back-activation of FXI, and enhances fibrin polymerization.190,193 On a weight basis, long-chain 
polyP is more potent than kaolin, an artificial surface, in activating the contact pathway;190 polyP 
is also orders of magnitude more potent –on both a weight and molar basis– than cell-free DNA 
or RNA when compared in a modified aPTT clotting assay (unpublished data).  
 
Conclusion 
 Traditionally, the contact pathway is initiated via the activation of FXIIa and propagated 
through the reciprocal activation of FXII and PK (in association with HK). Numerous potential 
physiologic activators of the contact pathway have come to light in recent years, increasing 
interest in the pathway and its potential role in vivo. PolyP, a highly negatively charged, linear 
polymer of orthophosphate residues held together by high-energy phosphoanhydride bonds is an 
exceptionally potent mediator of the contact pathway that is not only physiologically relevant, 
but exists across all branches of life. Fully understanding how this molecule mediates coagulation 
on a reaction level will be critical for a full appreciation of the role the contact pathway plays in 
both hemostasis and thrombosis. 
 Though the role of the contact pathway in normal hemostasis appears to be minimal, the 
opportunity for design of therapeutic approaches targeting components of the contact pathway to 
mitigate thrombosis are numerous. The contact pathway and its constituents are important 
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contributors to many thrombotic disorders and play important roles in linking coagulation and 
inflammation. Current antithrombotic therapies target common pathway coagulation factors; 
while this approach is often effective at lessening the risk of thrombotic events, it comes at the 
price of an increased risk of bleeding. In contrast, contact pathway coagulation factors and 
mediators are generally not required for normal hemostasis but have been shown to play 
important roles in the propagation of thrombosis. Thus, these components are enticing targets 
for new antithrombotic therapies. 
  
 
 
 
	 25	
CHAPTER 2: Mg2+ Effects on TF/FVIIa Activityb 
 
Abstract 
The blood coagulation cascade is initiated when the cell-surface complex of factor VIIa 
(FVIIa, a trypsin-like serine protease) and tissue factor (TF, an integral membrane protein) 
proteolytically activates factor X (FX). Both FVIIa and FX bind to membranes via their γ - 
carboxyglutamate-rich domains (GLA domains). GLA domains contain seven to nine bound 
Ca2+ ions that are critical for their folding and function, and most biochemical studies of blood 
clotting have employed supraphysiologic Ca2+ concentrations to ensure saturation of these 
domains with bound Ca2+. Recently, it has become clear that, at plasma concentrations of metal 
ions, Mg2+ actually occupies two or three of the divalent metal ion-binding sites in GLA 
domains, and that these bound Mg2+ ions are required for full function of these clotting proteins. 
In this study, we investigated how Mg2+ influences FVIIa enzymatic activity. We found that the 
presence of TF was required for Mg2+ to enhance the rate of FX activation by FVIIa, and we 
used alanine-scanning mutagenesis to identify TF residues important for mediating this response 
to Mg2+. Several TF mutations, including those at residues G164, K166, and Y185, blunted the 
ability of Mg2+ to enhance the activity of the TF/FVIIa complex. Our results suggest that these 
TF residues interact with the GLA domain of FX in a Mg2+ -dependent manner (although 
																																																						
b This chapter has been adapted in its entirety from an article originally published online in the journal Biochemistry, and used in 
accordance with the publisher’s copyright privileges for publication in a dissertation thesis. Full Citation: Gajsiewicz, J. M., et al. (2015). 
"Tissue Factor Residues That Modulate Magnesium-Dependent Rate Enhancements of the Tissue Factor/Factor VIIa Complex." 
Biochemistry 54(30): 4665-4671. 
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effects of Mg2+ on the FVIIa GLA domain cannot be ruled out). Notably, these TF residues are 
located within or immediately adjacent to the putative substrate-binding exosite of TF. 
 
Introduction 
The importance of divalent metal ions in blood coagulation reactions is well documented, 
as they play key roles in both protein-membrane and protein-protein interactions.12,39 Seven 
blood coagulation proteins interact reversibly with anionic membranes via their GLA domains, 
which are rich in the post-translationally modified amino acid, γ-carboxyglutamate (Gla). GLA 
domains bind multiple divalent metal ions,90 causing them to fold and form a characteristic ω-
loop structure, exposing hydrophobic residues that are believed to facilitate penetration of the 
membrane bilayer.194 
 The vast majority of biochemical studies of blood clotting proteins have employed 
supraphysiologic concentrations of Ca2+, which can occupy 7 to 9 metal ion-binding sites in the 
GLA domains of factors VII (FVII), IX (FIX) and X (FX).41,90,195,196 Ca2+ is the most prevalent 
divalent metal ion in plasma, with a free concentration of ~1.25 mM.197 However, biochemical 
studies of blood clotting proteins using 1.25 mM Ca2+ result in submaximal enzymatic activity 
and membrane binding, apparently because of incomplete saturation of the metal ion binding 
sites in the GLA domains of these proteins. For this reason, supraphysiologic Ca2+ 
concentrations (typically, 2.5 to 5 mM Ca2+) are typically employed in studies of blood clotting 
reactions. Recent studies, however, have shown that using the plasma concentrations of free Ca2+ 
(1.25 mM) together with the plasma concentration of free Mg2+ (~0.6 mM) results in clotting 
factor activities that are at least as high as those observed in the presence of supraphysiologic 
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[Ca2+].49,94,99,198,199 These studies therefore indicate that Mg2+ plays important, albeit somewhat 
overlooked, roles in blood clotting reactions. 
 In the present study, we examined how Mg2+ modulates the initiation phase of the blood 
clotting cascade. Blood clotting is triggered when the integral membrane protein, tissue factor 
(TF), binds FVIIa to form the TF/FVIIa complex. This complex activates FIX and FX by 
limited proteolysis. The mechanism(s) by which Mg2+ modulates the activity of clotting proteases 
is unclear, but recent crystal structures of FVIIa indicate that Mg2+ occupies 2 or 3 of the metal 
ion binding in its GLA domain under physiologic concentrations of Ca2+ and Mg2+,49 with 
structural implications.200 Persson et al.99 reported that removal of the FX GLA domain 
eliminated the ability of Mg2+ to increase the rate of FX activation by TF/FVIIa, suggesting that 
incorporation of Mg2+ into the GLA domain of FX may be the basis by which Mg2+ enhances 
FX activation. 
 We utilized site-directed mutagenesis of TF to investigate how Mg2+ modulates the 
activity of the TF/FVIIa complex. We confirm that TF is a key mediator of the Mg2+ response, 
despite its lack of direct interaction with either Ca2+ or Mg2+. We now identify individual TF 
residues within or near its putative substrate-binding exosite that are necessary for Mg2+ to 
enhance of the rate of FX activation by TF/FVIIa. Furthermore, we demonstrate that 
physiologic concentrations of Ca2+ plus Mg2+ support higher TF/FVIIa enzymatic activities than 
in the presence of Ca2+ alone, an effect that was more pronounced when more physiologic lipid 
compositions were utilized. Our findings support the idea that TF is an integral component of 
macromolecular substrate recognition by the TF/FVIIa complex, and that Mg2+ contributes to 
TF/FVIIa function. 
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Methods 
Materials.  
 Materials were from the following sources: phospholipids 1-palmitoyl-2-
oleoylphosphatidylcholine (PC) and 1-palmitoyl-2-oleoylphosphatidyl-L-serine (PS), Avanti 
Polar Lipids (Alabaster, AL); Bio-Beads® SM-2 absorbent, Bio-Rad; human FVIIa, American 
Diagnostica (now Sekisui Diagnostics, Lexington, MA); human FX, FXa, FIX, and FIXa, 
Haematologic Technologies (Essex Junction, VT); Spectrozyme Xa, Bachem (Bubendorf, 
Switzerland); Pefachrome FIXa, Enzyme Research Laboratories (South Bend, IN); and 
Chromozym t-PA, Roche Diagnostics (Mannheim, Germany).  
 
Production and relipidation of TF.  
 Recombinant human membrane-anchored TF (memTF, residues 3-244)201 and soluble 
TF (sTF, residues 3-219)202 were expressed in Escherichia coli and purified as previously 
described. TF mutants were prepared using the Q5 site-directed mutagenesis kit from New 
England Biolabs (Ipswich, MA). TF-liposomes were prepared by incorporating memTF into 
phospholipid vesicles of varying composition as described.203 
 
FVIIa Amidolytic Activity and Quantifying TF/FVIIa Binding.  
 Initial rates of hydrolysis of Chromozym-tPA substrate (FVIIa amidolytic activity) were 
measured essentially as previously described,61 in buffer containing either 1.25 mM CaCl2, 1.85 
mM CaCl2, or 1.25 mM CaCl2 plus 0.6 mM MgCl2. The affinity of FVIIa for TF was measured 
as described,15 using 5 nM FVIIa, 0-20 nM memTF, 1 mM Chromozym-tPA, and 0.1% Triton 
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X-100 in HBSA (20 mM HEPES pH 7.4, 100 mM NaCl, 0.02% sodium azide, 0.1% bovine 
serum albumin), either with 1.85 mM CaCl2, or with 1.25 mM CaCl2 plus 0.6 mM MgCl2. 
 
Rates of Activation of FX and FIX.  
 Initial rates of FX activation by TF/FVIIa using memTF, either in solution or relipidated 
into phospholipid vesicles, were quantified using a continuous FX activation assay as 
described,15,204 with slight modifications. Briefly, memTF and FVIIa were incubated essentially 
as described, but in buffers whose divalent metal ion concentrations were either 1.25 mM Ca2+, 
1.85 mM Ca2+, or 1.25 mM Ca2+ plus 0.6 mM Mg2+. Reactions were initiated by addition of 100 
nM FX and 1 mM Spectrozyme Xa. Reactions without membranes included 0.1% Triton X-100 
and typically employed 10 nM FVIIa and 500 nM memTF. Reactions with membranes typically 
employed 30-100 pM FVIIa and excess relipidated memTF (>1 nM memTF, with 25 µM total 
phospholipid).  
 Initial rates of FIX activation were quantified in a two-stage assay as described,70 with 
some variations. Briefly, FVIIa and memTF were incubated at 37°C for 5 min in buffer 
containing 0.06% Triton X-100 together with either 1.25 mM Ca2+ or 1.25 mM Ca2+ plus 0.6 
mM Mg2+. FIX was then added and incubated at 37°C, yielding typical final concentrations of 
20-40 nM FVIIa, 500 nM TF, and 1 µM FIX. Timed 10 µL aliquots were removed and 
quenched on ice using 10 µL of 20 mM EDTA in 10×HBSA. To quantify the FIXa generated, 
final concentrations of 40% ethylene glycol and 1 mM Pefachrome FIXa were added to 
quenched samples (total volume, 100 µL), and the rate of change in A405 was measured at 35°C. 
 
Solution NMR Spectroscopy.  
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 Purified sTF was concentrated using Amicon Ultra-15 centrifugal filters (EMD 
Millipore, Billerica, MA) with a Mr cutoff of 10 kDa, then dialyzed into 50 mM NaCl, 50 mM 
sodium phosphate (pH 6.5). Solution NMR samples were prepared with 100 µM sTF, 1 mM 
DSS (4,4,-dimethyl-4-silapentane-1-sulfonic acid) and 10% D2O along with 1.25 mM Ca2+, 0.5 
mM Mg2+, or no divalent cations. 15N-1H 2D HSQC correlation spectra were acquired on a 
Varian/Agilent VNMRS 17.6 T (750 MHz 1H frequency) spectrometer for 16.6 h each at 
~30°C. The measured pH values were 6.74, 6.78, and 6.79 for the samples with 1.25 mM Ca2+, 
0.5 mM Mg2+, and no divalent cations, respectively. Spectra were processed using NMRPipe205 
and chemical shifts were analyzed in SPARKY.206 
 
Results 
Components of the TF/FVIIa Complex Required for Mg2+-Dependent Rate Enhancements.  
 Although Mg2+ has been shown to modulate the enzymatic activity of FVIIa towards its 
cognate substrates, FIX94 and FX,49,93 and removal of the FX GLA domain abrogates this 
effect,99 a thorough understanding of how each component of the TF/FVIIa/membrane complex 
responds to Mg2+ has not yet been achieved. We therefore varied the constituents of this complex 
and examined the ability of Mg2+ to modulate the rate of FX activation by FVIIa. Figure 2.1 
shows the relative rates of FX activation by various components of the TF/FVIIa/membrane 
complex in the presence of physiologic concentrations of Ca2+ plus Mg2+ (1.25 mM and 0.6 mM, 
respectively), normalized to the rates observed with physiologic (1.25 mM) Ca2+ alone. For FVIIa 
in solution (no membranes or TF), the presence of Mg2+ plus Ca2+ actually decreased the rate of 
FX activation by 35% relative to Ca2+ alone. Mg2+ did not significantly influence the rate of FX 
activation by FVIIa in the presence of 30% PS/70% PC liposomes (but in the absence of TF; 
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second bar in Figure 2.1). In the presence of sTF but without membranes, Mg2+ enhanced the 
rate of FX activation by FVIIa by approximately 4-fold, consistent with previous findings.49,99 In 
the presence of sTF plus 30% PS/70% PC liposomes, Mg2+ still enhanced the rate of FX 
activation by FVIIa, but to a lesser extent than in the absence of membranes. Mg2+ also enhanced 
FX activation by FVIIa bound to relipidated TF, with the magnitude of the enhancement 
dependent on the lipid composition. Thus, Mg2+ enhanced the rate of FX activation in the 
presence of TF-liposomes containing either 100% PC or 5% PS/95% PC, but did not 
significantly enhance the rate of FX activation when TF-liposomes contained very high levels of 
PS (i.e., 30% PS/70% PC).  
 
TF Mutations That Diminish the Ability of Mg2+ to Enhance FX Activation by TF/FVIIa in 
Solution. 
 Previous studies identified a putative substrate-binding region (exosite) in TF, consisting 
of a patch of surface-exposed residues in the C-terminal fibronectin type III domain of this 
protein that are critical for recognition of macromolecular substrates (FVII, FIX, and FX) by the 
TF/FVIIa complex. In particular, mutating TF residues S163, K166, or Y185 to alanine 
substantially decreased the rates of FX activation by TF/FVIIa, while having little or no effect on 
the affinity of FVIIa for TF or on FVIIa amidolytic activity.70 We previously showed that if the 
GLA domain of FX is removed, mutations in the TF exosite no longer influence the rate of FX 
activation, suggesting that the FX GLA domain interacts with the TF exosite.69 Furthermore, 
Persson et al.99 showed that removing the FX GLA domain abrogated the ability of Mg2+ to 
enhance FX activation by TF/FVIIa. We therefore hypothesized that Mg2+ enhances the rate of 
FX action by TF/FVIIa largely by enhancing the interaction between FX and the substrate-
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binding exosite region of TF. To test this idea, we mutated 17 amino acids in memTF 
individually to alanine, chosen by their location within or adjacent to the putative substrate-
binding exosite.70 We expressed and purified these memTF mutants, then assessed the ability of 
Mg2+ to enhance the rate of FX activation by the resulting TF/FVIIa complexes. In particular, 
we compared three divalent metal ion conditions: 1.25 mM Ca2+ alone; 1.85 mM Ca2+ alone; and 
1.25 mM Ca2+ + 0.6 mM Mg2+. When we measured the rates of FX activation by memTF/FVIIa 
complexes in solution (i.e., with Triton X-100 and no membranes) in the presence of 1.85 mM 
Ca2+, we found that 13 of the 17 single amino acid mutations decreased the initial rate of FX 
activation by at least 50% relative to wild-type (WT) memTF, and that 6 of the mutations 
(Y157A, K159A, S163A, G164A, K166A, and Y185A) decreased the rate by at least 90% 
(Figure 2.2A). These results are in good agreement with those previously determined by 
Kirchhofer et al,70 which were obtained in the presence of phospholipid membrane surfaces. The 
absolute rates of FX activation obtained under each divalent metal ion condition that we tested 
are given in Table 2.1. 
 To determine how these TF mutations affected the ability of Mg2+ to enhance the 
enzymatic activity of memTF/FVIIa, we quantified initial rates of FX activation in the presence 
of 1.25 mM Ca2+ plus 0.6 mM Mg2+ and normalized those data to the rates using 1.85 mM Ca2+ 
alone (Figure 2.2B) or 1.25 mM Ca2+ alone (Figure 2.2C). The purpose of the former condition 
is to compare the combination of Ca2+ plus Mg2+ to an identical concentration of Ca2+ alone, 
such that the total divalent metal ion concentration is held constant at 1.85 mM. 
 Similar to the effect of Mg2+ we observed with sTF in solution, the combination of 1.25 
mM Ca2+ plus 0.6 mM Mg2+ enhanced the rate of FX activation by FVIIa bound to WT 
memTF in detergent solution by 4.4-fold compared to 1.85 mM Ca2+ alone (Figure 2.2B) and 
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6.0-fold compared to 1.25 mM Ca2+ alone (Figure 2.2C). The TF exosite mutants fell into two 
main categories with regard to their sensitivity to Mg2+. The first category included mutations 
that were highly deleterious for FX activation but which nevertheless showed essentially the same 
ability of Mg2+ to enhance the rate of FX activation observed with WT memTF/FVIIa 
complexes. Thus, TF mutants W158A, S160A, S162A, E174A, L176A and R200A exhibited 
absolute rates of FX activation less than 75% of WT memTF (Figure 2.2A), yet showed 
essentially the same response to the combination of Ca2+ plus Mg2+ versus Ca2+ alone that was 
observed for WT memTF (Figures 2.2B and 2.2C). The second category included mutants 
Y157A, S163A, G164A, K159A, K165A, K166A and Y185A that exhibited both substantially 
decreased absolute rates of FX activation (Figure 2.2A) and substantially blunted ability of Mg2+ 
to enhance their rates of FX activation (Figures 2.2B and 2.2C). On the other hand, no TF 
mutants were identified that retained WT absolute rates of FX activation yet were deficient in 
their response to Mg2+. A similar pattern of results was obtained when we examined the ability of 
Mg2+ to enhance the rate of FIX activation by this collection of memTF mutants (Figure 2.6). 
 To better understand our results, we also investigated the effect of simply increasing the 
Ca2+ concentration from 1.25 to 1.85 mM on the rate of FX activation by memTF/FVIIa 
complexes in solution (Figure 2.7). With WT TF, increasing the Ca2+ concentration resulted in 
an approximately 1.3-fold increase in the rate of FX activation. Within experimental error, most 
of the TF mutants supported similar increases in the rate of FX activation upon increasing the 
Ca2+ concentration. Two TF mutants (K159A and K165A) were significantly different, 
exhibiting approximately 30% slower rates of FX activation at 1.85 mM Ca2+ compared to 
1.25 mM Ca2+ (Figure 2.7). 
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TF Mutations That Diminish the Ability of Mg2+ to Enhance FX Activation by TF/FVIIa on 
Membranes.  
 Our studies thus far have examined the ability of Mg2+ to increase the rate of FX by 
TF/FVIIa complexes in solution. We next examined the effects of eleven selected TF mutants in 
experiments in which memTF was incorporated into liposomes of varying phospholipid 
composition (Figure 2.3). As was also seen in Figure 2.1, the ability of the combination of 1.25 
mM Ca2+ plus 0.6 mM Mg2+ to enhance the rate of FX activation relative to 1.85 mM Ca2+ alone 
using WT TF was a function of the PS content of the TF-liposomes. Thus, as the PS content 
increased, the ability of Mg2+ to enhance the rate of FX activation decreased, reaching an 
essentially negligible level of enhancement by Mg2+ at 15% PS. For clarity, we grouped the TF 
mutants in three panels of Figure 2.3 according to their ability to support Mg2+-dependent 
enhancement of the rate of FX activation in solution. Thus, those memTF mutants that 
supported essentially WT responses to Mg2+ in solution (W158A, S162A, E174A and D178A) 
also exhibited increased rates of FX activation in the presence of Mg2+ when employed in 
liposomes (Figure 2.3A). Although increasing the PS content of the TF-liposomes tended to 
blunt the Mg2+ response in these mutants, the effect of increasing the PS content on the Mg2+ 
response was generally less extensive than that observed with WT TF. This was most particularly 
true of the S162A mutant. 
On the other hand, the memTF mutants that supported intermediate responses to Mg2+ in 
solution (Y157A, K159A, S163A, and K165A) exhibited essentially no response to Mg2+ in 
liposomes (Figure 2.3B). And finally, the memTF mutants that exhibited the most deficient 
responses to Mg2+ in solution (G164A, K166A and Y185A) actually exhibited, in liposomes, 
lower rates of FX activation in the presence of Mg2+ plus Ca2+ compared to Ca2+ alone (Figure 
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2.3C). Furthermore, the blunted responses to Mg2+ by the TF mutants in Figures 2.3B and 2.3C 
were observed irrespective of the PS content of the memTF-liposomes. 
 
Solution NMR Spectroscopy of sTF in the Presence of Divalent Cations.  
To investigate whether TF interacts directly with the divalent cations Ca2+ and Mg2+, we 
utilized solution NMR spectroscopy to compare 15N-1H 2D heteronuclear single quantum 
coherence (HSQC) correlation spectra in the presence and absence of these ions. As shown in 
Figure 2.4, addition of physiologic divalent cation (either 1.25 mM Ca2+ or 0.5 mM Mg2+) to 
100 µM sTF samples resulted in no significant shifts in peak positions in 15N-1H 2D correlation 
spectra. These results are consistent with the idea that neither Ca2+ nor Mg2+ interact directly 
with sTF in a specific manner, which in turn is consistent with available x-ray crystal structures 
in which neither Ca2+ nor Mg2+ have been observed bound to sTF.41,49 
 
Discussion 
 Divalent cations such as Ca2+ and Mg2+ are critical components of blood coagulation, 
supporting both protein-protein and protein-membrane interactions. While the contributions of 
Ca2+ to blood coagulation reactions have been extensively studied, the roles of Mg2+ are less well 
understood. In this study, we confirmed that TF is required for Mg2+ to enhance the rate of 
activation of FIX or FX by FVIIa,99 and we showed that specific residues in the putative 
substrate-binding region of TF contribute to this Mg2+-dependent rate enhancement. Although 
TF is an allosteric regulator of the general catalytic activity of FVIIa, this function is 
independent of the presence of Mg2+ as long as Ca2+ is available, since adding Mg2+ has no 
significant effect on FVIIa amidolytic activity,99 nor does it enhance the affinity of FVIIa for TF 
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(Table 2.2). Thus, enhancement of TF/FVIIa catalytic activity by Mg2+ is restricted to 
macromolecular substrates (FIX and FX). Importantly, a previous study showed that removing 
the FX GLA domain eliminated the ability of Mg2+ to enhance the rate of FX activation by 
TF/FVIIa,99 and our lab previously demonstrated that the GLA domain of FX must be intact for 
mutations in the TF exosite to have any effect on the rate of FX activation by TF/FVIIa.69 These 
results support the idea that the FX GLA domain interacts directly with the TF exosite and is of 
critical importance for Mg2+ recognition. This does not preclude the involvement of FVIIa in 
mediating these interactions; indeed, a recent study reported that the FVIIa GLA domain must 
also be intact for Mg2+ to enhance the rate of FX activation by TF/FVIIa.27  
 Our working hypothesis to explain all these findings is that Mg2+ promotes the binding of 
FX (or FIX) to the exosite region of TF. To accomplish this, Mg2+ could, in principle, be 
contributing to increase rates of FX activation via its binding to the GLA domains of either 
FVIIa or FX, or perhaps even binding to TF. (Since we observe the effect of Mg2+ in solution, it 
is not necessary to invoke association of Mg2+ with phospholipids, and therefore Mg2+ must be 
promoting protein-protein interactions.) Our NMR results, together with a wealth of x-ray 
crystal structures, argue strongly that Mg2+ does not associate measurably with TF. Under 
physiologic concentrations of divalent metal ions, Mg2+ is thought to occupy at least two, and 
possibly three or four metal ion-binding sites in the GLA domains of both FVIIa and FX.207 
Although our results do not allow us to determine whether Mg2+ binding to FVIIa or FX is more 
important for enhancing the rate of FX activation, one can speculate that occupancy of the FX 
GLA domain with Mg2+ may increase the affinity of this domain for the TF exosite. Mg2+ 
binding to the FVIIa GLA domain may also play a regulatory role, as comparison of crystal 
structures in the presence or absence of Mg2+ indicates that conformational changes occur in the 
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FVIIa GLA domain upon Mg2+ occupancy.200 Interestingly, the 159-165 loop of sTF was 
disordered when the sTF/FVIIa complex was crystallized with Ca2+ only, but was ordered when 
crystallized in the presence of both Ca2+ and Mg2+. How these structural changes might affect 
TF/FVIIa activity towards its cognate substrates is currently unclear. 
 For better visual interpretation, we mapped the mutations in this study onto the x-ray 
crystal structure of the FVIIa/sTF complex, colored according to their impact either on the 
absolute rate of FX activation (Figure 2.5A) or on the ability of Mg2+ to enhance the rate of FX 
activation (Figure 2.5B) by memTF/FVIIa in solution. In Figure 2.5C, we also graphed the 
effects of these mutations, plotted as ability of Mg2+ to enhance the rate of FX activation (y-axis) 
versus absolute rate of FX activation (x-axis), with data points colored using the same scheme as 
Figure 2.5B. The deleterious effects of these TF exosite mutations on the absolute rate of FX 
activation (Figure 2.5A) largely confirm the findings of Kirchhofer et al.70 Only a subset of these 
mutations, however, reduced the ability of Mg2+ to enhance the rate of FX activation, with 
mutations G164A, K166A and Y185A (colored blue in Figure 2.5B) essentially eliminating the 
Mg2+ effect; notably, these three mutations also severely reduced the absolute rate of FX 
activation (colored blue in Figure 2.5A). TF mutations Y157A, S163A, K165A and D180A 
(colored green in Figure 2.5B) exhibited a more moderate, yet still significant reduction in the 
Mg2+ effect; of these, three (Y157A, S163A and K165A) greatly reduced the absolute rate of FX 
activation (colored blue in Figure 2.5A), while one (D180A) had a more moderate reduction in 
the absolute rate of FX activation (colored green in Figure 2.5A). TF mutant K159A severely 
reduced the absolute rate of FX activation, but did not significantly diminish the Mg2+ effect 
relative to WT TF. The remaining ten mutations also did not significantly reduce the ability of 
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Mg2+ to enhance the rate of FX activation relative to WT TF, irrespective of whether they 
decreased the absolute rate of FX activation. 
 The location of TF residues that mediate Mg2+-dependent rate enhancement suggests 
that a critical component of the TF/FVIIa interaction with Mg2+-bound FX substrate involves 
the flexible TF loop located at residues 160-165, with the adjacent residues Y185, K166, K159, 
and Y157 also involved. These residues, in particular 164-166, are highly conserved across 
mammalian species (Figure 2.8). The importance of G164 to Mg2+ recognition is particularly 
interesting, as glycine lacks a functional side chain with which to interact with macromolecular 
substrates. A possible explanation is that this highly conserved glycine permits flexibility or 
orientations of the adjacent loop(s) that are otherwise not possible with amino acids containing 
bulkier side chains. 
 When WT memTF was incorporated into liposomes, we found that increasing the PS 
content of the membranes blunted the response to Mg2+, confirming our previous findings.93 We 
also found that increasing the PS content of TF-liposomes blunted the Mg2+ response in these 
TF mutants. With several of these mutants (especially S162A), this blunting effect of PS was less 
extensive than that observed with WT TF. We also found that the TF mutants that were most 
deficient in response to Mg2+ when tested in solution (G164A, K166A and Y185A) actually had 
lower rates of FX activation in TF-liposomes in the presence of Mg2+ plus Ca2+ compared to Ca2+ 
alone. Furthermore, the essentially negative effects of Mg2+ on this class of TF mutants were 
observed irrespective of the PS content of the memTF-liposomes. 
 Messer et al. have shown that occupancy of the FIXa GLA domain with Mg2+ enhances 
its affinity for PS-containing membranes, and have proposed that Mg2+ generally enhances the 
membrane binding of GLA domain-containing clotting proteins.208 If this is part of the 
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mechanism by which Mg2+ enhances the rate of FX activation by TF/FVIIa (i.e., by better 
recruiting FX to the membrane surface in the vicinity of TF/FVIIa and thereby raising the local 
substrate concentration), then it follows that increasing the PS content may blunt the Mg2+ 
effect, since greatly raising the PS content will likewise increase the affinity of FX for the 
membrane surface and thus overshadow the relative contribution from Mg2+. However, the fact 
that some TF mutations selectively abolish the ability of Mg2+ to enhance the rate of FX 
activation by the TF/FVIIa/membrane complex argues in favor of protein-protein interactions 
(presumably, between the TF exosite and the GLA domain of FX) being also very important in 
mediating the ability of Mg2+ to enhance the proteolytic activity of TF/FVIIa toward FIX and 
FX.
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CHAPTER 3: Relative Contributions of Nucleic Acids and PolyP to Coagulation 
 
Abstract 
Polyphosphate and nucleic acids are linear, anionic polymers that contribute to 
thrombosis in animal models and may be important in thrombotic diseases in humans. 
Polyphosphate plays several roles in coagulation and in particular may be one of the long-sought 
(patho)physiologic initiators of the contact pathway; extracellular DNA and RNA have been 
implicated as initiators of coagulation and as biomarkers for disease states, including sepsis. In 
this study, we directly compared the procoagulant activities of polyphosphate, DNA and RNA, 
in order to understand their relative effectiveness in initiating and accelerating blood clotting 
reactions. Since polyphosphate, DNA, and RNA have similar physical properties, we 
hypothesized that polyphosphate and nucleic acids might co-purify using conventional 
techniques for isolating DNA or RNA from cells or tissues. We found that long-chain 
polyphosphate was a far more potent contact pathway activator than DNA or RNA. 
Polyphosphate also potently abrogated the anticoagulant activity of tissue factor pathway 
inhibitor (TFPI), whereas DNA and RNA were relatively ineffective. Polyphosphate readily co-
purified with DNA and RNA using several popular procedures for isolating nucleic acids. 
Furthermore, treatment of human cell-derived DNA with either nucleases or phosphatases 
abrogated its procoagulant ability, and trace contamination of these samples with polyphosphate 
was confirmed and quantified. Our findings indicate that long-chain polyphosphate is two to 
three orders of magnitude more potent at triggering clotting than either DNA or RNA, and 
suggest that polyphosphate contamination of nucleic acid preparations may contribute to their 
observed procoagulant activities. 
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Introduction 
 
Recent advances in understanding the contributions of the contact pathway of blood 
clotting to thrombosis, inflammation, and innate immunity209 have generated renewed interest in 
identifying the (patho)physiologic activators of this pathway. Proposed candidates include 
collagen,210 misfolded proteins,211 DNA, RNA,212 and polyphosphate (polyP).213 PolyP, consisting 
of linear polymers of inorganic phosphate held together by phosphoanhydride bonds, is widespread 
in biology.214 Work from our laboratory and others has identified important procoagulant and 
proinflammatory roles of polyP.215 We have also shown that the precise contributions of polyP to 
blood clotting are strongly dependent on its polymer length.215,216 
 Many microorganisms accumulate polyP that is heterogeneous in length.214,217 A number of 
mammalian tissues reportedly contain polyP, such as brain, heart, lung, bone and prostate.218-221 
Long-chain polyP (up to thousands of phosphates long), such as that found in microorganisms,217 
elaborated by prostate cancer cells,221 and possibly found in mammalian brain,218 is an especially 
potent activator of the contact pathway of coagulation.216 Shorter-chain polyP (roughly 60 to 120 
phosphates), such as that secreted by activated platelets, mast cells and basophils,186,220,222 only very 
weakly activates the contact pathway.216 On the other hand, platelet-size polyP is highly active in 
modulating downstream clotting reactions, including promoting factor XI activation by 
thrombin,156 promoting factor V activation by multiple proteases,215 enhancing fibrin clot 
structure,193,223 and abrogating the anticoagulant function of tissue factor pathway inhibitor 
(TFPI).213 
PolyP and nucleic acids are both linear polymers with regularly spaced, anionic phosphate 
groups, so it is perhaps not surprising that they may have similar activities toward blood clotting 
reactions. The possible contributions of extracellular nucleic acids to coagulation and inflammation 
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are under intense investigation, with a number of studies reporting the procoagulant effects of cell-
free RNA212 and DNA,176,224,225 particularly in the context of neutrophil extracellular traps.173,226,227 
Although multiple groups have reported the ability of nucleic acids and polyP to activate the 
contact pathway, head-to-head comparisons of the relative procoagulant abilities of these anionic 
polymers are largely lacking. 
The anionic nature of DNA and RNA is commonly exploited for their purification from 
cells and tissues, and many commercially available nucleic acid purification kits are based on silica 
or ion exchange resins. These same approaches are also employed for polyP purification, using 
either finely powdered silica216,228 or anion-exchange columns.221,229 We therefore hypothesized 
that polyP might co-purify with nucleic acids using standard DNA or RNA purification 
techniques. If so, then some or all of the previously reported procoagulant properties of nucleic 
acids might be due to polyP contamination. 
 In this study, we demonstrate that polyP is two to three orders of magnitude more active 
than DNA or RNA in triggering the contact pathway of blood clotting, and is also far more 
effective than nucleic acids at abrogating TFPI function. We also report that several 
commercially-available nucleic acid purification kits result in DNA or RNA preparations that are 
contaminated with sufficient amounts of polyP to substantially alter their apparent procoagulant 
properties. 
   
Materials and Methods 
Materials 
PolyP was size-fractioned as described216 to obtain preparations indicated as: short-chain 
polyP (mode, 75 phosphates; range, 20 – 330 phosphates); medium-chain polyP (mode, 385 
	 43	
phosphates; range, 265 – 630 phosphates); and long-chain polyP (mode, 1320 phosphates; 
range, 430 to more than 2000 phosphates). All polyP concentrations are given in terms of 
phosphate monomers. 
 Citrated pooled normal plasma was from George King Biomedical. Liposomes were 
made by sonication using phospholipids from Avanti Polar Lipids (85% 1-palmitoyl-2-
oleoylphosphatidylcholine/15% 1-palmitoyl-2-oleoylphosphatidyl-L-serine). Recombinant 
human TFPI was as described.230 Calf intestinal alkaline phosphatase (CIAP) was from Promega 
and lambda DNA, HindIII-digested lambda DNA, 1kb DNA ladder, Low MW DNA ladder, 
and 100 bp DNA ladder were from New England Biolabs. SYBR Green I (SYBR) was from 
FMC BioProducts. Benzonase, 4',6-diamidino-2-phenylindole (DAPI), and RNA 
homopolymers (polyguanylate, polyG; polyinosinate, polyI; polyadenylate, polyA; or 
polycytidylate, polyC) were from Sigma-Aldrich. A size comparison of polyP and RNA 
homopolymers is given in Figure 3.7.  
 
Isolation of cell-derived nucleic acids  
HEK 293 cells were grown to confluence in Dulbecco's Modified Eagle Medium with 
10% fetal bovine serum and penicillin-streptomycin, and harvested for isolation of DNA and 
RNA. Cell-free DNA was purified using DNeasy Blood & Tissue kit (Qiagen), while total 
cellular RNA was purified using RNeasy Midi kit (Qiagen), according to the manufacturer’s 
instructions. DNA from multiple purifications was pooled and concentrated in 3,000 molecular 
weight-cutoff centrifugal filters (Millipore). Nucleic acid concentrations were determined by 
light absorption at 260 nm. 
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Comparison of polyP recovery rates using nucleic acid purification kits 
DNeasy Blood and Tissue kit, RNeasy Mini kit, Qiaquick PCR Purification kit 
(Qiagen), and TRIzol Reagent (Invitrogen) were evaluated for their recovery rates when used to 
“purify” samples consisting of nucleic acid alone (either phage lambda DNA or polyG), or 
nucleic acid mixed with long-chain polyP. We employed 5 µg of each nucleic acid and polyP for 
such experiments with the DNeasy, RNeasy, and TRIzol kits, and 2.5 µg of each nucleic acid 
and polyP for the Qiaquick kit (because of its lower capacity). Instructions for the DNeasy kit 
vary according to source material, so the protocol for “cultured cells” was followed and the 
optional second elution of DNA was included. For the RNeasy kit, the protocol was followed for 
samples with less than 5 x 106 animal cells; the optional membrane-drying spin was included, but 
the optional on-column DNase digestion was omitted. Sample preparation for TRIzol 
purification used the protocol for suspension cells. The TRIzol reagent allows for isolation of 
both RNA and DNA; we performed sequential isolation of nucleic acids and/or polyP from both 
the aqueous (RNA-containing) and interphase/organic (DNA-containing) layers as described in 
the manufacturer’s instructions.  Nucleic acid concentrations were determined by light 
absorption at 260 nm. PolyP concentrations were determined following complete digestion with 
recombinant yeast exopolyphosphatase (PPX1, purified as described231), after which the released 
monophosphate was quantified by PiBlue assay (BioAssay Systems). 
 
Evaluation of polyP contamination in cell-derived DNA 
DNA purified from HEK293 cells using the DNeasy Blood & Tissue kit was digested 
with Benzonase to hydrolyze the nucleic acids, after which any residual polyP was isolated as 
described221 with minor modifications. Briefly, 8M LiCl and 4.5M NaI were added to the 
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samples, which were then applied to EconoSpin DNA spin columns (Epoch Life Sciences). 
Columns were washed 5 times with a solution of 50% ethanol, 100 mM NaCl, 10 mM Tris pH 
7.5, 1 mM EDTA, after which polyP was eluted in purified water. The polyP was then digested 
with PPX1 and the released monophosphate quantified as described above. HEK293 cell DNA, 
Benzonase-digested HEK293 cell DNA, and HindIII-digested lambda DNA were subjected to 
PAGE on 4-20% gels and visualized with SYBR Green I for nucleic acid, or by DAPI staining 
for polyP (negative fluorescent staining after photobleaching) and nucleic acid (positive 
fluorescence) as described.232 
 
Enzymatic digestions of DNA and polyP 
DNA or polyP preparations were digested in 20 mM HEPES pH 7.4, 5 mM NaCl, 5 
mM KCl for 30 minutes at 37°C with either 700 U/mL Benzonase, 300 U/mL CIAP, or no 
enzyme. 
 
Contact pathway-initiated plasma clotting assays 
Plasma clotting times were quantified in duplicate at 37°C by mixing 50 µL of activator 
(nucleic acid or polyP in 20 mM HEPES pH 7.4, 5 mM NaCl, 5 mM KCl with 75 µM 
liposomes) and 50 µL of plasma in wells of medium-binding 96-well polystyrene microplates 
(Corning). After 3 minutes, 50 µL of pre-warmed 25 mM CaCl2 in 20 mM HEPES was added 
and mixed in by trituration. Light scattering (absorbance at 405 nm) was monitored in a 
SpectraMax 340PC microplate reader (Molecular Devices) at 37°C. Clot times were determined 
as previously described233 and normalized to the mean clot time for plasma without activator. 
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Figure 3.8 shows the distribution of clot times in the absence of activator. For evaluation of 
enzymatically digested preparations of polyP or nucleic acids, clot times in the presence of 
activator (nucleic acid or polyP) were normalized to the clot time in the absence of activator but 
with the corresponding enzymatic treatment.  
 
Abrogation of the anticoagulant activity of TFPI 
TFPI abrogation was evaluated using clotting assays essentially as described.216 Anionic 
polymers were diluted in nuclease-free water (Amresco). Final reactions contained 17 mM Tris-
HCl pH 7.4, 50 mM NaCl, 0.7% bovine serum albumin, 33 µM liposomes, 8.33 mM CaCl2, 
and 33% plasma, with or without 200 ng/mL TFPI. Clot times with added polyanion were 
normalized to clot times for plasma plus TFPI but without polyanion. 
 
Results 
PolyP is a much more potent and efficacious contact pathway activator than cellular DNA or 
RNA 
Previous work by our lab and others has shown that both polyP and nucleic acids trigger 
clotting via the contact pathway.166,191 Table 3.1 outlines the techniques used in a number of 
publications to isolate nucleic acids for investigations into their procoagulant properties. Though 
numerous tissue-, source-, and application-specific kits exist, in general, silica-based purification 
columns are most commonly utilized. Because of this, we isolated total cellular DNA and RNA 
from cultured HEK 293 cells using two of the most popular commercial kits from Qiagen: 
DNeasy Blood & Tissue kit for DNA and RNeasy Midi kit for RNA. 
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To compare the relative procoagulant activities of nucleic acids and polyP, we utilized a 
modified activated partial thromboplastin time clotting assay in which varying concentrations of 
polyP, RNA or DNA were added to plasma to trigger clotting via the contact pathway. As 
previously reported,216 polyP shortened the time to clot formation in a manner that was 
dependent on both concentration and polymer length (Figure 3.1A). Short-chain polyP had 
limited ability to trigger clotting in this assay. Medium- and long- chain polyP were highly 
procoagulant, exhibiting maximal shortening of the clot time by 83% and 89%, respectively, at 2 
µg/mL polyP 
 In contrast, HEK 293 cell-derived nucleic acids and lambda DNA were weaker and less 
potent than polyP in triggering plasma clotting, on both a mass (Figure 3.1A) and a molar 
(Figure 3.9) basis. For HEK 293 cell-derived DNA, maximal shortening of clot time was 52% at 
75 µg/mL, while for lambda DNA, maximal shortening was 25% at 50 µg/mL. HEK 293 cell-
derived RNA was even less effective in triggering clotting, shortening the clot time by only 10% 
at a concentration of 100 µg/mL (Figure 3.1A). 
 To further investigate the proposed procoagulant activity of RNA,212,234 we evaluated the 
ability of synthetic RNA homopolymers to activate the contact pathway (Figure 3.1B). While 
polyA and polyC had virtually no detectable procoagulant effect, polyG and polyI were effective 
at triggering plasma clotting, exhibiting bell-shaped concentration dependences, similar to polyP. 
In particular, polyG exhibited a maximal 85% decrease in clot time at 10 µg/mL, and was 
therefore almost as effective as long-chain polyP in triggering clotting. 
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Ability of polyP versus nucleic acids to abrogate TFPI anticoagulant activity 
PolyP is highly effective at abrogating the anticoagulant activity of TFPI in plasma 
clotting assays, likely by accelerating factor V activation213,235 and blocking TFPI targeting of the 
prothrombinase complex.236 As we reported previously,216 short-chain polyP completely 
abrogated TFPI function at polyP concentrations above 5 µg/mL (Figure 3.2). In contrast, HEK 
293 cell-derived DNA and RNA exhibited limited ability to reverse the anticoagulant activity of 
TFPI over a range of concentrations tested. On the other hand, the synthetic RNA 
homopolymer, polyI, completely abrogated TFPI anticoagulant activity with a potency similar to 
that of polyP. PolyA and polyG showed more limited ability to reverse TFPI anticoagulant 
activity, requiring more than tenfold higher concentrations compared with polyP or polyI. PolyC 
was ineffective. 
 
Digestion of cell-derived DNA with nuclease or polyphosphatase decreases its procoagulant 
activity 
Because polyP and nucleic acids are both linear, anionic polymers, we hypothesized that 
methods for isolating nucleic acids might also co-purify polyP. If so, then some or all of the 
apparent procoagulant activity of cell-derived DNA might be attributable to contaminating 
polyP. DNA isolated from HEK 293 cells using the DNeasy kit had detectable procoagulant 
activity when tested at 50 µg/mL (Figure 3.3A). Digesting this DNA preparation with either a 
highly active nuclease (Benzonase), or CIAP, which is a highly active exopolyphosphatase,237 
resulted in complete loss of clotting activity (Figure 3.3A). As a control, we found that 
Benzonase digestion of 2 µg/mL long-chain polyP had an insignificant effect on its procoagulant 
activity, while CIAP digestion eliminated its procoagulant activity (Figure 3.3B). Interestingly, 
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the procoagulant effect of 20 µg/mL bacteriophage lambda DNA, which we hypothesized would 
be unlikely to contain polyP, was not diminished by CIAP but was abrogated by Benzonase 
(Figure 3.3B). We confirmed that Benzonase had no detectable polyphosphatase activity and 
that CIAP had no detectable nuclease activity (Figure 3.10). 
 
The procoagulant effects of polyP and DNA are additive  
To examine if polyP and DNA might cooperate to initiate clotting, we evaluated the 
procoagulant activity of lambda DNA to which polyP had been added (Figure 3.4A). Mixing 20 
µg/mL lambda DNA with varying concentrations of short-chain polyP consistently shortened 
the clot times across a range of polyP concentrations (0.1 to 10 µg/mL polyP). Mixing 20 µg/mL 
lambda DNA with medium-chain polyP did not alter the clotting times observed at polyP 
concentrations at or above 2 µg/mL, but did shorten the clotting times at all polyP 
concentrations from 0.1 to 1 µg/mL. 
 
Small amounts of polyP enhance the procoagulant effects of DNA 
Any possible contamination of nucleic acids with polyP would likely scale relative to the 
amount of DNA purified. Kumble and Kornberg218 found that the concentration of polyP in 
mammalian tissues and cell lines to be approximately 1% that of DNA. We consequently 
evaluated the procoagulant ability of medium-chain polyP added to lambda DNA at a fixed ratio 
of 1:100 on a mass basis (Figure 3.4B). Lambda DNA with 1% added medium-chain polyP was 
more procoagulant than either medium-chain polyP alone, HEK 293 cell DNA alone, or lambda 
DNA alone. 
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Nucleic acids and polyP co-purify using several popular kits for nucleic acid isolation 
To examine whether polyP will co-purify with nucleic acids, we quantified the recovery 
of nucleic acids and polyP using a variety of commercially available kits for isolating DNA or 
RNA (Figure 3.5). In these experiments, known quantities of lambda DNA or polyG, either 
alone or mixed with long-chain polyP, were re-purified using Qiaquick, DNeasy, or TRIzol kits, 
following the manufacturer’s instructions. Purification of DNA with either the Qiaquick or 
DNeasy kit resulted in 40-60% recovery of the applied DNA, and adding polyP to the sample 
did not diminish the DNA recovery. Purification of RNA with the RNeasy Miniprep kit 
resulted in ~50% RNA recovery, regardless of whether polyP was present. Similarly, the presence 
of polyP did not diminish RNA recovery from either the aqueous or organic phase when using 
TRIzol Reagent (Figure 3.5).  
When polyP was present in the starting nucleic acid sample, it was readily recovered with 
the DNA or RNA using all the kits tested (Figure 3.5). The Qiaquick kit yielded ~55% of the 
starting polyP, when purified alone or in the presence of DNA. With the DNeasy kit, polyP 
recovery was higher (91%) when DNA was present in the sample than when DNA was absent 
(79%). PolyP (58%) was also recovered with the RNeasy kit. Little or no polyP was recovered in 
the aqueous phase of TRIzol (which is typically used to isolate RNA), while 50-60% of polyP 
was recovered in the organic phase (which typically contains DNA). 
 HEK 293 cell-free DNA purified using the DNeasy kit and lambda DNA were resolved 
by PAGE, after which the gel was stained sequentially with DAPI (which stains DNA 
fluorescently and which shows strong photobleaching for polyP232) followed by SYBR Green I 
(which fluorescently stains DNA but not polyP) (Figure 3.6). Lambda DNA fluoresced with 
both stains, which was abolished by Benzonase pretreatment. HEK 293 cell DNA was also 
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positively fluorescent with both stains, but we also observed photobleaching during DAPI 
staining in the faster-migrating portions of this lane beginning immediately below the DNA and 
continuing as a streak towards the bottom of the gel, suggesting the presence of polyP (Figure 
3.6A, lane 2) Pretreatment of HEK 293 cell DNA with Benzonase eliminated the positive 
fluorescence and left only the faster-migrating, photobleached material near the bottom of the 
gel, indicative of the presence of polyP (Figure 3.6A, lane 4). HEK 293 gave no fluorescence 
with SYBR Green I after Benzonase treatment, confirming its complete degradation by this 
nuclease (Figure 3.6B, lane 4). 
 We next quantified the polyP present in DNA that had been isolated from HEK 293 
cells with the DNeasy Blood and Tissue Kit. After treatment with Benzonase to digest DNA, 
polyP was purified and quantified as described in Materials and Methods. We recovered 1.9 
nmoles of polyP-derived monophosphate from the DNA sample that contained 1.23 µmoles of 
nucleotides (assuming an average nucleotide molecular weight of 327 Da). Thus, the polyP 
content in this sample, on a molar basis, was 0.16% that of DNA (i.e., moles of phosphate in 
polyP relative to moles of nucleotide in DNA). 
 
Discussion 
Here we report a head-to-head comparison of the procoagulant activities of DNA, RNA 
and polyP, all of which have been proposed to be significant pathophysiologic activators of the 
contact pathway and modulators of downstream clotting reactions. Medium- and long-chain 
polyP were two to three orders of magnitude more potent than human cell-derived DNA or 
RNA, and resulted in considerably shorter clotting times. We also tested DNA purified from 
bacteriophage lambda, reasoning that it was likely not to be contaminated with polyP, and found 
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that lambda DNA was indeed appreciably less procoagulant than an equivalent concentration of 
human cell-derived DNA. One possible explanation for this difference is that the human cell-
derived DNA is contaminated with polyP. Given the much higher procoagulant activity of 
polyP, even trace contamination of DNA with polyP might significantly alter its apparent 
procoagulant activity. Digestion of HEK 293 cell-derived DNA with the nuclease, Benzonase, 
rendered its clotting activity undetectable; however, digestion with CIAP, which is a very active 
exopolyphosphatase, also rendered its procoagulant activity undetectable. Notably, treatment of 
lambda DNA with CIAP had no effect on its procoagulant activity, while Benzonase treatment 
completely abolished its activity. These results support the notion that contaminating polyP 
contributes to the contact pathway activation observed with mammalian cell-derived DNA. Our 
results can be explained if the observed procoagulant activity is due to a combination of a high 
concentration of DNA (which has weak potency as a procoagulant) plus trace concentrations of 
contaminating polyP (which has high potency as a procoagulant). If so, then elimination of 
either component leaves undetectable procoagulant activity. 
 Previous work has focused on the possible procoagulant activity of RNA, in part because 
RNase A decreased the procoagulant activity of cell lysates and was protective in in vivo models 
of thrombosis.212 In contrast, we found cell-derived RNA to be a weak contact pathway activator, 
reducing the clot time by only 10% even at concentrations that were orders of magnitude higher 
than optimal concentrations of long- or medium-chain polyP. On the other hand, we found that 
RNA homopolymers composed of polyG or polyI were highly procoagulant, both activating the 
contact pathway and abrogating TFPI anticoagulant activity. These results indicate that the 
procoagulant nature of these molecules is not an intrinsic property of RNA in general, but rather 
highly dependent on base composition. The finding that the homopolymers polyG and polyI 
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have procoagulant properties similar to polyP, but that polyA and polyC have little to no 
procoagulant activity, suggests that polynucleotide structure plays an important role in 
determining the procoagulant activity of nucleic acids. Indeed, Gansler et al.176 recently reported 
that hairpin-containing RNA and DNA oligonucleotides, as well as oligonucleotides that adopt 
quadruplex structures and small nucleolar RNAs, exhibited the greatest ability to shorten plasma 
clotting times and promote PPK autoactivation. Both polyG and polyI can form G-quadruplexes 
in the presence of Na+ or K+,238,239 and similar structures have previously been shown to bind 
thrombin.240,241 Furthermore, telomeric DNA and its RNA transcription products are rich in G-
quadruplex repeats,242 and DNA G-quadruplexes have been visualized in human cells.243 Our 
findings confirm and extend those of Gansler et al.176 and suggest that non-canonically base-
pairing sequences of DNA or RNA are particularly procoagulant when released from cells. 
We determined that polyP contamination of HEK 293 cell-derived DNA constituted 
about 0.16% of the total phosphate. This is slightly lower than that previously suggested by 
Kumble and Kornberg;218 however, this level of contamination is consistent with the 
procoagulant activity we measured when adding polyP to purified bacteriophage lambda DNA at 
a 1/100 mass ratio, which had a procoagulant activity that exceeded that of DNA isolated from 
HEK 293 cells. 
In summary, we have demonstrated that polyP co-purifies with nucleic acids when 
utilizing traditional purification methods that have been used by others for coagulation 
experiments,212,225,244 and that the observed procoagulant effects of mammalian cell-derived DNA 
are due in part to contaminant polyP. Medium- and long-chain polyP are 2 to 3 orders of 
magnitude more potent contact pathway activators than total cell DNA or RNA, and yield far 
shorter clotting times. PolyP is present in mammalian cells at much lower concentrations than 
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DNA;218 however, the greater potency and efficacy of polyP suggests that even trace 
contamination of cell-derived nucleic acid preparations with polyP could contribute substantially 
to the observed procoagulant properties. Indeed, it seems likely that a combination of 
extracellular nucleic acids and polyP contribute to clotting reactions in vivo, but this needs to be 
tested explicitly. Future studies exploring the procoagulant effects of nucleic acids derived from 
cellular sources should include removal or neutralization of possible contaminating polyP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 55	
CHAPTER 4: Characterization of Polyphosphate- and Ribonucleic Acid-Mediated Contact 
Pathway Activation 
Abstract 
The contact pathway of the blood clotting cascade is dispensable for normal hemostasis 
but contributes to thrombosis and serves as a bridge between inflammation and coagulation. This 
pathway is triggered upon exposure of plasma to certain anionic polymers and artificial surfaces. 
Recently, several potential (patho)physiologically relevant activators of this pathway have been 
identified, including extracellular nucleic acids and inorganic polyphosphate (polyP). However, 
mechanistic details regarding how nucleic acids or polyP modulate the individual reactions of the 
contact pathway have been lacking. In this study, we investigate the ability of RNA 
homopolymers and polyP to bind the primary constituents of the contact pathway: factor XI, 
factor XII, and plasma prekallikrein, in the presence and absence of high molecular weight 
kininogen (HK), an important cofactor in this pathway. We examined seven proteolytic 
activation reactions within the contact pathway and report that polyP greatly enhances the rate of 
all seven, while RNA is effective in supporting only a subset of these reactions. HK both 
enhances and suppresses these proteolytic activation reactions, depending on the specific reaction 
evaluated. Overall, we find that polyP is a potent mediator of contact pathway activation 
reactions in general, that RNA secondary structure may be important to its procoagulant activity, 
and that nucleic acids versus polyP may differentially modulate specific enzyme activation events 
within the contact pathway.  
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Introduction 
The contact pathway of blood clotting is initiated when plasma is exposed to anionic 
surfaces and substances such as glass and clay.245,246 This mechanism for triggering clotting is 
irrelevant to normal hemostasis, since severe deficiencies in either of the two key enzymes that 
trigger this pathway, factor XII (FXII)247 or plasma prekallikrein (PPK),248 are not associated 
with bleeding tendencies in humans. However, recent findings have implicated the contact 
pathway in thrombosis, inflammation and innate immunity. Thus, in models of venous 
thrombosis, mice deficient in FXII249-251 are protected, and pharmacologic targeting of either 
FXII or PPK is protective.252 Animal models of arterial thrombosis have also indicated a 
protective effect of FXII deficiency;251,253,254 FXII contributes to thrombus stability on 
atherosclerotic plaques;255 and several studies have reported a correlation between myocardial 
infarction and elevated plasma levels of contact pathway proteins.126,129,256 FXII also plays a 
central role in hereditary angioedema.209  
 This renaissance in the contact pathway has led to renewed interest in understanding its 
true pathophysiologic triggers. Recently identified candidates include collagen210 and misfolded 
proteins,211 as well as the linear, anionic polymers, polyphosphate (polyP),213,222,257 DNA,173,225-227 
and RNA.212 Long-chain polyP and extracellular RNA appear to be particularly active at 
triggering the contact pathway and are implicated in thrombosis and inflammation.209,257 The 
goal of the present study is to achieve better mechanistic insights into how polyP and RNA 
trigger the contact pathway. 
 Figure 4.1 is a schematic overview of how this pathway is initiated, with the present study 
examining how polyP and RNA influence the rates of each of the numbered proteolytic events in 
this figure. The majority of PPK and factor XI (FXI) circulate in plasma bound to high 
	 57	
molecular weight kininogen (HK),258-260 so PPK and FXI are depicted in complex with HK. 
Whether the active enzymes – plasma kallikrein (PK) or factor XIa (FXIa) – remain associated 
with HK is not so clear, but we have chosen to depict them as complexes in this figure. This 
pathway is initiated when zymogen factor FXII undergoes autoactivation and/or allosteric 
activation upon interaction with certain anionic surfaces or polymers.118,246 The resulting active 
enzyme, FXIIa, converts PPK to PK, creating a positive feedback loop through reciprocal 
activation of PPK by FXIIa, and FXII by PK.261 Once sufficient FXIIa is generated, it activates 
factor XI (FXI), leading to propagation of the coagulation cascade and, ultimately, fibrin 
formation. 
HK is not only an important cofactor for triggering the contact pathway, but it is also 
acted upon proteolytically by PK, resulting in the release of the vasodilator peptide, 
bradykinin.250,262 Because bradykinin is a potent vasoactive mediator, it represents an important 
link between the coagulation cascade and inflammation. Binding of PPK and FXI to certain 
anionic surfaces is greatly enhanced by HK263,264 and HK is required in stoichiometric amounts 
for maximal enzymatic activity in vitro.264 Although single-chain HK can bind to, and serve as, a 
cofactor for FXI and PPK, the proteolytically cleaved two-chain form of HK is a much more 
efficient cofactor, likely due to the fact that the two-chain protein binds with higher affinity to 
anionic polymers and surfaces.263  
 To date, limited studies have investigated the ability of polyP or RNA to accelerate the 
rates of the individual reactions of the contact pathway. In the present study, we show that polyP 
and RNA exert differential effects on these individual enzyme activation reactions, both in the 
presence and absence of HK. 
 
	 58	
Materials and Methods 
Materials.  
Synthetic RNA homopolymers (polyguanylic acid, polyG; polyinosinic acid, polyI; 
polyadenylic acid, polyA; and polycytidylic acid, polyC), hirudin, and soybean trypsin inhibitor 
(STI) were from Sigma (St. Louis, MO). Human FXII, α-thrombin, FXI, FXIa, and corn 
trypsin inhibitor (CTI) were from Haematologic Technologies (Essex Junction, VT); PPK, PK, 
α-FXIIa and single-chain HK were from Enzyme Research Laboratories (South Bend, IN). 
Chromogenic substrates for FXIa (Pyr-Pro-Arg-pNA) and FXIIa or PK (H-D-Pro-Phe-Arg-
pNA) were from Bachem (Bubendorf, Switzerland). 
 Polyanion concentrations are given in terms of the concentration of phosphate 
monomers, i.e. phosphate concentration for polyP and nucleotide concentration for nucleic acids. 
Narrowly size-fractionated long-chain polyP (size range: 1110 - 1540) and biotinylated polyP 
(size range: 110 – 385 phosphates) were prepared as previously described.192,216 
 
Competition Binding Assays.  
The ability of RNA homopolymers and polyP to bind to proteins of the contact pathway 
was investigated using a plate-based competition assay essentially as described.192,265 Briefly, 10 
μM biotin-polyP was captured on streptavidin-coated microplate wells. FXIa, FXIIa, or PK (at 
50 nM) were incubated in the wells together with various competitors at ambient temperature 
for 1 h in 20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM NaCl, 10 μM ZnCl2, 1% 
polyethylene glycol (8000 MW), 0.05% Tween-20. In some experiments, 50 nM HK was also 
included. Wells were washed and the bound enzyme was quantified via amidolytic activity (rate 
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of cleavage of the appropriate chromogenic substrate), compared to a standard curve with known 
enzyme concentrations. 
 
General Conditions for Enzyme-Substrate Reactions.  
Enzyme activation reactions (including autoactivation reactions) were generally carried 
out at 37°C in 20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM NaCl, 1% polyethylene glycol 
(8000 MW). 10 μM ZnCl2. 
In discontinuous assays, the ice-cold quench buffer (HEP) was 20 mM HEPES pH 7.4, 
5 mM EDTA, and 15 μg/mL polybrene (as an inhibitor of the polyanions). Titration 
experiments were performed to determine the polyanion concentration (tested from 1.25 to 
100 μM) that resulted in the maximal enzyme activation rate, and that polyanions concentration 
was used for further experiments. Amidolytic activities of the various enzymes were quantified in 
a Spectramax M2 96-well spectophotometer (Molecular Devices) by measuring the change in 
A405 for 1 h using 0.4 mM of the appropriate chromogenic substrate, typically at ambient 
temperature (except for PK, which was quantified at 37 °C in order to prevent temperature-
dependent autoinhibition of this enzyme266). 
 
Activation of FXI by Thrombin or FXIIa.  
Rates of FXI activation were quantified using a discontinuous assay as previously 
described,156,267 with minor modifications. Briefly, 40 nM of FXI dimer was incubated with 15 
nM thrombin or 5 nM FXIIa in the presence or absence of polyanion. In some experiments, 40 
nM HK was also included. Timed aliquots of 20 μL were removed and quenched on ice in 
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80 μL HEP plus an inhibitor of either thrombin (18 U/mL hirudin) or FXIIa (500 nM CTI) as 
appropriate. The FXIa concentration at each quenched time point was determined by measuring 
its amidolytic activity, with reference to a standard curve. 
 
Autoactivation of FXI.  
Second-order rate constants for FXI autoactivation (FXI activation by FXIa) were 
determined using a discontinuous chromogenic assay. 100 pM FXIa dimer was incubated with 
40 nM FXI dimer in the presence or absence of polyanion; 40 nM HK was included in some 
reaction mixtures. Timed aliquots were removed and quenched on ice in HEP, after which FXIa 
amidolytic activity was quantified. Data were analyzed according to a second-order reaction 
mechanism (FXIa + FXI à 2FXIa) and as described previously for autoactivation reactions.6,268 
 
FXI Autolysis.  
FXI autolysis was measured essentially as previously described.156 Briefly, FXIa (40 nM) 
and HK (40 nM) were incubated at 37°C in the presence of 1.25 μM polyI or 5 μM polyP, and 
timed aliquots were removed and quenched with in HEP buffer on ice. Residual FXIa activity 
was quantified using 0.4 mM FXIa chromogenic substrate with reference to a standard curve. 
 
Autoactivation of FXII or PPK.  
A discontinuous assay was used to quantify FXII autoactivation similarly to that 
previously described.269 200 nM FXII and 200 nM HK were incubated with polyanion. Timed 
aliquots of 20 μL were quenched on ice in 80 μL HEP, after which FXIIa amidolytic activity 
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was quantified. The FXIIa concentration at each quenched time point was determined by 
measuring its amidolytic activity, with reference to a standard curve. In separate experiments, 
continuous assays for FXII or PPK autoactivation employed zymogen (either 200 nM FXII or 
100 nM PPK) pre-mixed with chromogenic substrate. Solutions were warmed at 37°C for 3 min, 
and polyanion was added to initiate the reaction. Rates of chromogenic substrate hydrolysis were 
measured at 37°C. Enzyme concentrations were then calculated from the first derivative of A405 
vs. time; second-order rate constants were derived as described.6,268 
 
Activation of FXII by PK, and PPK by FXIIa.  
In discontinuous assays, zymogen and enzyme were incubated with polyanions, with or 
without 200 nM HK. For PK activation of FXII, the concentrations were 1 nM and 200 nM 
respectively. For FXIIa activation of PPK, the concentrations were 250 pM and 50 nM 
respectively. Timed aliquots were quenched on ice in HEP plus inhibitor for the activating 
enzyme (50 μg/mL STI for PK, 500 nM CTI for FXIIa). Enzyme concentrations were 
quantified via amidolytic activity, with reference to a standard curve. 
 
Results 
FXI Binding and Rates of FXI Activation.  
Polyanions such as polyP192,270 and dextran sulfate271 have been reported to facilitate FXI 
activation. To investigate the ability of FXI to bind to RNA, we utilized a microplate-based 
binding assay in which various RNA homopolymer (or polyP) in solution competed with 
immobilized polyP for binding to FXI (Figure 4.2). Since Zn2+ has been reported to enhance the 
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binding affinities and activities of several of the proteins of the contact pathway,272,273 including 
FXI(a) (unpublished data), we employed 10 μM ZnCl2 in essentially all the assays in this study. 
PolyG, polyI, and polyP in solution were effective competitors for the binding of FXIa to 
immobilized polyP, while neither polyA nor polyC appreciably reduced FXIa binding. Addition 
of HK did not appreciably alter the outcome of this competition binding experiment with regard 
to any of the polymers tested. 
 FXI can be activated in three reactions, all of which are enhanced by polyanions; the 
relevant proteases, numbered as in Figure 4.1, are: (5) FXIa (autoactivation), (6) FXIIa, and (7) 
thrombin. PolyP strongly enhanced the rate of FXI autoactivation (confirming our previous 
reports156,267), while polyI was much less effective and polyG did not support this reaction (Figure 
4.2B). Inclusion of HK reduced the rate of polyP-mediated FXI autoactivation by as much as 
60% (Figure 4.2C). HK also shifted the polyP concentration dependence such that maximal 
autoactivation required twice as much polyP (5 μM polyP in the presence to HK). On the other 
hand, HK did not appreciably alter the rate of polyI-mediated FXI autoactivation (Figure 4.2C). 
 PolyG, polyI and polyP greatly enhanced the rate of FXI activation by thrombin (Figure 
4.2D), by at least 75-fold compared to vehicle control. Of these, polyG was the least effective, 
supporting rates about one-quarter of those with polyP or polyI. Adding HK reduced the rate at 
which thrombin activated FXI by 30-40% for all three polyanions (Figure 4.2D). This is 
consistent with a previous report in which HK reduced the rate of FXI activation by thrombin by 
about 50% in the presence of sulfatides or heparin.271 
 At a suboptimal concentration of polyP, 1.25 μM, polyP enhanced the rate of FXI 
activation by FXIIa relative to the vehicle control, but the rate gradually slowed over 5 to 10 min 
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(Figure 4.2E). The same trend was also seen with both polyG and polyI, but occurred at all 
concentrations of polyG and polyI tested (Figure 4.2E). In contrast, in the presence of polyP at 
the optimal concentration of 2.5 μM, linear rates of FXIa generation were observed over the 30 
min time course (Figure 4.2F); polyP supported initial rates of 0.41 ± 0.06 and 0.44 ± 0.06 
nM/min in the presence and absence of HK, respectively (compared to 0.01 ± 0.001 nM/min in 
the absence of polyP or HK; Figure 4.2F). Adding HK did not appreciably alter the rates of FXI 
activation with any of the polyanions tested (Figure 4.2E,F). 
 PolyP-mediated FXI autolysis had been previously demonstrated in the absence of HK.156 
We found that both polyP and polyG were able to support FXI autolysis in the presence of HK, 
with rates of 1.22 ± 0.16 and 0.55 ± 0.18 nM/min, respectively. The polyP-mediated rate of 
autolysis in the presence of HK was comparable to that in its absence. 
 
FXII Binding and Rates of FXII Activation.  
PolyG, polyI and polyP in solution were effective competitors of FXIIa binding to 
immobilized polyP, while polyA and polyC were ineffective (Figure 4.3A). HK did not 
appreciably alter the competition binding results.  
Autoactivation of single-chain FXII on anionic surfaces to the two-chain active enzyme, 
α-FXIIa, was thought to be the initial enzymatic step in the contact pathway. However, a recent 
study reported significant enzymatic activity of single-chain FXII in complex with polyP, which 
appears to function as an allosteric activator of this zymogen.269 In discontinuous assays of FXIIa 
generation in which time aliquots were quenched with polybrene (to disrupt FXII(a) binding to 
polyP), we found that polyP supported very little FXIIa generation via autoactivation in the 
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presence or absence of HK (Figure 4.3B), consistent with the findings of Engel et al.269 On the 
other hand, both polyG and polyI supported generation of readily detectable FXIIa activity, 
although this was observed only in the presence of HK (Figure 4.3B). 
In a continuous assay in which a chromogenic substrate was included with FXII and 
polyP, we found that polyP led to robust FXII(a) amidolytic activity (Figure 4.3C), though this 
could not be fit to a second order rate equation. PolyG and polyI also supported this reaction, 
though to a lesser extent (Figure 4.3C), and the data was fit to a second order rate equation and 
quantified (Figure 4.3D). In the presence of HK, polyG enhanced the rate of FXII 
autoactivation 8-fold when compared to the vehicle control, while polyI mediated a 6.8-fold 
increase. Though we were unable to quantify the second order rate constant for polyP-mediated 
autoactivation, a qualitative assessment of substrate generation (Figure 4.3C) indicates that the 
fold enhancement would be greater than that for either polyG or polyI. Inclusion of HK 
enhanced the FXII(a) activity 68% and 76% in the presence of polyG and polyI, respectively 
(Figure 4.3D).  
 We next evaluated the abilities of polyG, polyI and polyP to support FXII activation by 
PK. In the absence of HK, all three anions enhanced the rate of FXIIa generation, with polyG 
and polyI, yielding 5- and 27-fold greater activity, respectively, than with polyP (Figure 4.3E). 
HK further enhanced the rates of FXII activation by PK in the presence of all three polyanions, 
but most profoundly for polyP (17-fold increase by HK) (Figure 4.3E).  
 
(P)PK Binding and Rates of PPK Activation.  
PK at 50 nM did not bind detectably to immobilized polyP in the absence of HK (not 
shown), but did bind in the presence of 50 nM HK (Figure 4.4A). In the presence of HK, 
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polyG, polyI and polyP in solution were equally effective competitors of PK binding to 
immobilized polyP, while polyA and polyC were ineffective. 
 In a continuous assay of PPK autoactivation, none of the polyanions supported 
appreciable substrate hydrolysis in the absence of HK (Figure 4.4B). In the presence of HK, 
polyG, polyI and polyP all supported robust PK enzyme activity. The second-order rate 
constants for PPK autoactivation in the presence of HK supported by polyG, polyI or polyP are 
presented in Figure 4.4C. The rate supported by polyP was approximately 40% higher than that 
with polyG or polyI. 
 We next examined the effect of polyanions and HK on the rate of activation of 50 nM 
PPK by 250 pM FXIIa. In the absence of HK, polyP, polyG, and polyI all substantially 
enhanced the rate of PPK activation, to a roughly equal extent. Adding 50 nM HK enhanced the 
rate of PPK activation even in the absence of anions. Adding polyG or polyI plus HK resulted in 
little further enhancement of the rate compared with HK alone, while adding polyP plus HK 
roughly doubled the rate compared with HK alone (Figure 4.4D).   
 
Discussion 
The contact pathway acts as a bridge between coagulation and inflammation and plays 
important roles in thrombosis. Recent work has identified a number of physiologic activators of 
the contact pathway; however, a systematic interrogation of the effects of procoagulant 
polyanions on each step in the contact pathway was lacking. In this study, we compared the 
interactions between various procoagulant polyanions and the enzymes of the contact pathway, 
and assessed the contributions of HK to these reactions. We found that procoagulant polyanions 
differ greatly in how they impact the enzymatic steps constituting contact pathway activation, 
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and that HK both potentiates and suppresses polyanion-mediated activation depending on the 
reaction being investigated.  
 An intriguing observation in this work is the related to the multivariate nature of the 
effects of the polyanions on the contact pathway. PolyP supported every reaction tested, and was 
the most potent polyanion for all autoactivation reactions. PolyI also supported every reaction, 
and was most effective at supporting FXI back-activation by thrombin and FXII activation by 
PK. PolyG, on the other hand, was a relatively poor supporter of FXI back-activation by 
thrombin and did not support FXI autoactivation. A visual representation of the contact pathway 
is shown in Figure 4.1, with each reaction labeled. In Figure 4.5, a qualitative table summarizes 
the relative effects of the various polyanions and HK on the contact pathway enzyme/substrate 
reactions. Our findings highlight the mechanistic heterogeneity with which the anionic surfaces 
function and reinforce the need to study the contact pathway at both the pathway and protein 
level. They also open the door to the possibility that in vivo activation of the contact pathway 
should not be considered a single event, but rather as a collection of reciprocal and feedback 
reactions, the balance of which may result in small –but potentially important –phenotypic 
differences. 
  Our investigations into the rate of FXI activation by FXIIa produced interesting results, 
with FXIa activity over time plateauing in the presence of polyG or polyI. The endpoint 
measurement of this experiment, FXIa activity, is likely affected by the combination of three 
reactions: FXI activation by FXIIa, FXI autoactivation, and FXI autolysis. We previously found 
that FXI undergoes autolysis in the presence of polyP,156 and have found that polyI also supports 
FXIa autolysis. Furthermore, the activation of FXI by FXIIa in the presence of suboptimal 
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quantities of polyP (1.25 μM) resulted in non-linear FXIa activity curves similar to those seen 
with polyG and polyI (Figure 4.2E). At this lower concentration (1.25 μM), polyP-mediated 
FXI autoactivation is less than 10% of the maximal observed rate when using 2.5 μM polyP 
(unpublished results). Taken together, these results suggest that the non-linear FXI activation 
curves seen for polyG and polyI in Figure 4.2E are a function of poorly supported FXI 
autoactivation and shifting equilibriums between the three concurrent reactions.  
 When comparing the qualitative results shown in Figure 4.5, a potentially important 
observation can be seen in the differing abilities of polyP and nucleic acids to support the 
activation of FXI by FXIIa (Figure 4.5, reaction 6). FXI activation by FXIIa is believed to be an 
important activation mechanism, especially with regard to thrombosis,254 and serves as the single, 
critical bridge between the contact and common pathways of coagulation. Our findings show 
that polyP mediates a strong and sustained FXI activation, whereas polyG and polyI only 
support an initial, small burst of FXIa generation. These differences may contribute greatly to 
the increased procoagulant effects of polyP compared to nucleic acids, and also suggest that 
downregulating FXIIa-mediated activation of FXI through the inhibition of polyP might be a 
potentially useful antithrombotic approach.  
 Our findings here confirm those of Engel et al.,269 who reported that polyP “activates” 
FXII by inducing reversible conformational changes in the single-chain protein. This mechanism 
of action appears to be unique to polyP; polyG and polyI both induced FXIIa activity in the 
discontinuous FXII activation assay, indicating proteolytic cleavage and formation of two-chain 
FXIIa. Interestingly, FXII autoactivation by either mechanism appears to be greatly enhanced in 
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the presence of HK despite the fact that HK is not generally thought to be a relevant cofactor for 
FXII(a).  
 Our findings indicate that PK only binds to polyanions in the presence of HK, and that 
HK is required for PPK autoactivation. HK also enhances polyP-mediated activation of PPK by 
FXIIa 2-fold. These results indicate that the activation of PPK is enhanced by HK regardless of 
the activating enzyme, and that future in vitro studies of polyanion-mediated contact pathway 
activation using purified proteins should be carried out in the presence of HK.  
 A comparison of second-order rate constants for FXII and PPK autoactivation in the 
presence of HK under ideal activating conditions highlights a fascinating finding; rates of PPK 
autoactivation with polyG, and polyI are 7.3-, and 11.2-fold higher than the autoactivation rates 
for FXII. Furthermore, PPK is present at slightly higher plasma concentrations than FXII (~580 
vs. ~375 nM), and the majority of PPK in plasma is bound to HK, conceivably able to undergo 
autoactivation. These findings open the door to the possibility that the contact pathway is 
initiated, at least in part, through the autoactivation of PPK in the presence of physiologic 
polyanions. 
 We previously reported that cell-derived nucleic acids have only limited ability to activate 
that contact pathway (Unpublished experiments). Among the RNA homopolymers, only polyG 
and polyI had detectable contact activation in plasma-based assays. The purified protein studies 
presented here confirm and extend those observations. PolyA and polyC did not bind to any of 
the contact pathway proteins, thus only polyG and polyI were able to support the various 
enzymatic reactions of the contact pathway. This is further evidence that the procoagulant nature 
of RNA is sequence-specific and not an intrinsic property of RNA.  
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 Although polyP and RNA homopolymers are both polyanions, the size of the repeating 
unit in polyP is markedly smaller than that in RNA. The differences between the polyP and 
RNAs with regards to their spectra of effects may be in part related to the charge spacing within 
the polymers. Alternatively, it may be more a function of flexibility and the capacity to form 
secondary structure. Previous work by Gansler et al.176 demonstrated the importance of secondary 
structure on the procoagulant ability of nucleic acids; hairpin forming RNA oligomers are not 
only more resistant to degradation but are also more procoagulant, as structure-forming RNA 
aptamers were shown to be able to mediate the autoactivation of PPK. PolyG and polyI are 
known to form stable, non-canonical base-pairing structures termed G-quadruplexes.238,239 
Though our studies did not specifically probe structural considerations, our findings suggest that 
secondary structure is likely a factor contributing to the procoagulant properties of nucleic acids. 
Our findings also suggest the intriguing notion that possible secondary structures of polyP in 
solution might contribute to its interactions with contact factors.  
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FIGURES AND TABLES 
 
 
Figure 1.1. Crystal structures of FVIIa and sTF arranged on a membrane surface. A) FVIIa 
(blue) has an extended conformation and binds to anionic phospholipids in membrane bilayers 
through its N-terminal GLA-domain (depicted here in contact with the membrane). 
Coordination of divalent cations such as Ca2+ (red spheres) and Mg2+ (gray spheres) by the GLA 
domain is critical for proper domain folding and function. In addition, a Ca2+ ion is bound to the 
first EGF-like domain of FVIIa and also to the protease domain of this protein (the domain 
farthest from the membrane). The isolated ectodomain of TF (sTF, orange) is depicted here as 
anchored to the membrane surface via a single transmembrane helix, which has been modeled in. 
Full-length TF also contains a 21 amino acid-long cytoplasmic tail (not shown) which is 
implicated in interactions with the cytoskeleton. B) Crystal structure of the sTF-FVIIa complex, 
with the transmembrane helix of TF modeled in. FVIIa interacts extensively with sTF, with a 
binding interface that spans all domains of FVIIa and sTF. C) Close-up of TF residues 
putatively involved in substrate recognition (i.e., the substrate-binding exosite region of TF). In 
addition to allosterically activating FVIIa, TF is thought to directly interact with the protein 
substrates, FIX and FX, through membrane-proximal residues. Thus, TF residues Tyr157, 
Lys159, Ser163, Gly164, Lys165, Lys166, and Tyr185 (shown as van Der Waals radii and 
colored according to identity as follows; Teal: Lysine, White: Glycine, Yellow: Serine, Green: 
Tyrosine) contribute significantly to interactions with substrate as demonstrated by mutagenesis 
studies. (Panel C is rotated ~45° from panel B.) The structure of the sTF-FVIIa complex in 
panels B and C is rendered from pdb file 3TH2274 using VMD Molecular Graphics Viewer.275 
The isolated structures of FVIIa and sTF shown in panel A are a separation of the two from the 
TF-FVIIa complex. The transmembrane helix attached to sTF is adopted from pdb file 1A11.276 
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Figure 2.1. Effect of Mg2+ on FX activation by FVIIa in the presence or absence of TF or 
membranes. FX activation by FVIIa was measured in the presence of the components listed, 
with a dash (—) indicating the component was not present. Data are mean initial rates of FX 
activation in the presence of 1.25 mM Ca2+ + 0.6 mM Mg2+ normalized to rates using 1.25 mM 
Ca2+ alone. Error bars are one standard error (n ≥ 3). Normalized rates that are statistically 
significantly different from 1.0 are indicated with an asterisk (one-sample t-tests; p < 0.05). 
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Figure 2.2. Effect of TF mutations on rates of FX activation by memTF/FVIIa in solution (with 
0.1% Triton X-100), measured using different divalent metal ion concentrations. (A) FX 
activation by memTF/FVIIa using 1.85 mM Ca2+ alone, graphed as initial rates of FX activation 
divided by the memTF/FVIIa concentration. (B) Relative rates of FX activation by 
memTF/FVIIa in solution using 1.25 mM Ca2+ + 0.6 mM Mg2+, normalized to rates using 
1.85 mM Ca2+ alone. (C) Relative rates of FX activation by memTF/FVIIa in solution using 
1.25 mM Ca2+ + 0.6 mM Mg2+, normalized to rates using 1.25 mM Ca2+ alone. Data are mean ± 
standard error (n ≥ 3). 
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Figure 2.3. Effect of eleven selected TF mutations on the ability of Mg2+ to enhance the rate of 
FX activation by TF/FVIIa/membrane complexes. WT or mutant memTF was incorporated 
into liposomes containing 0-15% PS, with the balance being PC. Initial rates of FX activation by 
the resulting memTF/FVIIa complexes were measured with 1.25 mM Ca2+ plus 0.6 mM Mg2+, 
and normalized to the rates observed with 1.85 mM Ca2+ alone. The memTF mutants are 
grouped in the three panels as described in the text, with the same data for WT memTF 
() plotted in each panel for comparison. (A) Normalized rates of FX activation observed with 
memTF mutants S162A (Î), W158A (q), E174A (s), and D178A (ó). (B) Normalized rates 
of FX activation observed with memTF mutants S163A (£), K165A (¿), K159A (), and 
Y157A (p). (C) Normalized rates of FX activation observed with memTF mutants Y185A (r), 
K166A (¢), and G164A (¯). Data are mean ± standard error (n ≥ 3). 
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Figure 2.4. Lack of detectable effect of divalent metal ions on NMR spectra of sTF. (A) 15N-1H 
2D HSQC correlation spectrum of 100 µM sTF in 50 mM sodium phosphate, 50 mM NaCl, 1 
mM DSS, 10% D2O and no divalent metal ions (blue) overlaid with the sTF spectrum in the 
same buffer plus 1.25 mM Ca2+ (red). (B) 15N-1H 2D HSQC correlation spectrum of 100 µM 
sTF in the same buffer as in panel A, without divalent metal ions (blue) overlaid with the 
spectrum in the presence of 0.5 mM Mg2+ (green). (C) Chemical shift perturbations upon 
titration with 1.25 mM Ca2+ (from panel A) calculated as δ = ([0.1δN]2 + δH2)1/2), with an average 
chemical shift perturbation of 0.0014 ppm. (D) Chemical shift perturbations upon titration with 
0.5 mM Mg2+ (from panel B), with an average chemical shift perturbation of 0.0015 ppm. Of the 
208 expected non-proline resonances in sTF, 196 resonances were assigned. 
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 Figure 2.5. Localization and properties of TF residues investigated. The structure is from PDB 
file 3TH2, in which sTF/FVIIa was crystallized in the presence of 5 mM Ca2+ and 2.5 mM 
Mg2+.200 FVIIa is depicted as orange ribbons, with bound Ca2+ ions in teal and Mg2+ ions in 
beige. (A) Localization of the TF residues tested in this study for their effect on the absolute rate 
of FX activation by memTF/FVIIa in solution. TF residues are color-coded according to their 
rate of FX activation in the presence of 1.85 mM Ca2+ alone (from Figure 2.2A). Unmutated TF 
residues are white. TF residues are colored red which, when mutated, retained essentially WT 
activity (i.e., ≥ 75% of WT rate of FX activation). Residues with moderate effect on FX 
activation rate are green (30-75% of WT); residues with severe defects are blue (≤ 30% of WT). 
Residues W158 and S160, obstructed in the visualization above, are colored blue and green, 
respectively. (B) Localization of TF residues tested in this study as being important for the ability 
of Mg2+ to enhance the rate of FX activation by memTF/FVIIa in solution. TF residues are 
color-coded according to their rate of FX activation in the presence of Ca2+ plus Mg2+ normalized 
to the rate at 1.85 mM Ca2+ alone (from Figure 2.2B). Unmutated TF residues are white. TF 
residues are colored red which, when mutated, retained essentially WT responses to Mg2+ (i.e., 
4- to 6-fold enhancement in FX activation rate). Residues with blunted responses to Mg2+ are 
colored green (2- to 4-fold enhancement by Mg2+) or blue (1- to 2-fold enhancement by Mg2+). 
Residues W158 and S160, obstructed in the visualization above, are colored red. (C) Relative 
rate of FX activation (rate with 1.25 mM Ca2+ + 0.6 mM Mg2+, divided by rate with 1.85 mM 
Ca2+) versus the absolute rate of FX activation, in both cases by memTF/FVIIa in solution (i.e., 
data re-plotted from Figures 2.2A and 2.2B, respectively). Residues are color-coded as in panel B 
of this figure. Vertical black dotted lines correspond to the color-coding cutoff values from panel 
A; horizontal black dotted lines correspond to the color-coding cutoff values from panel B. 
Vertical dotted red line marks the location of WT TF. Experiments were performed by Kristin 
Nuzzio. 
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Table 2.1. Effect of Mg2+ on Rates of FX Activation by memTF/FVIIa in Solution 
 Initial rates of FX activation (nM/min/nM ×103)a 
TF 
(WT or mutant) 
1.25 mM Ca2+ + 0.6 mM 
Mg2+ 1.85 mM Ca
2+ 1.25 mM Ca2+ 
WT 122.1 ± 4.0 27.8 ± 3.9 20.4 ± 1.3 
Y157A 5.3 ± 0.4 2.2 ± 0.1 1.7 ± 0.1 
W158A 30.8 ± 2.8 7.2 ± 0.3 5.4 ± 0.6 
K159A 10.3 ± 2.0 2.8 ± 0.2 4.0 ± 1.9 
S160A 58.2 ± 4.0 12.1 ± 2.2 7.1 ± 0.2 
S161A 189.4 ± 17.2 31.4 ± 2.8 24.3 ± 1.1 
S162A 47.3 ± 1.8 9.4 ± 0.6 6.5 ± 0.4 
S163A 2.8 ± 0.5 1.0 ± 0.1 0.9 ± 0.1 
G164A 1.1 ± 0.2 0.8 ± 0.1 0.8 ± 0.1 
K165A 4.8 ± 0.2 1.8 ± 0.1 2.4 ± 1.0 
K166A 2.5 ± 0.4 1.5 ± 0.2 1.4 ± 0.3 
K169A 133.9 ± 12.9 25.0 ± 1.4 17.4 ± 1.1 
E174A 98.3 ± 3.3 18.9 ± 1.0 13.0 ± 1.1 
L176A 60.8 ± 4.2 12.5 ± 0.5 7.4 ± 0.4 
D178A 129.5 ± 15.0 24.2 ± 1.5 19.1 ± 2.5 
D180A 34.4 ± 4.9 13.1 ± 2.3 8.8 ± 0.8 
Y185A 2.3 ± 0.2 1.8 ± 0.1 1.4 ± 0.1 
R200A 29.0 ± 1.8 5.9± 0.5 3.8 ± 0.3 
aData are initial rates of FX activation in (nM/min) divided by the memTF/FVIIa 
concentration (in nM), expressed as mean ± standard error (n ≥ 3). Reaction conditions were 10 
nM FVIIa, 500 nM memTF, 0.1% Triton X-100, 100 nM FX, and 1 mM Spectrozyme Xa. 
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Figure 2.6. Effect of TF mutations on Mg2+-dependent rate enhancements of FIX activation. 
(A) Initial rates of FIX activation by WT or mutant memTF/FVIIa in solution (with 0.06% 
Triton X-100) using 1.25 mM Ca2+. (B) Relative rates of FIX activation by WT or mutant 
memTF/FVIIa in solution (with 0.06% Triton X-100). In this panel, the rates using 1.25 mM 
Ca2+ + 0.6 mM Mg2+ were normalized to those using 1.25 mM Ca2+ alone. Data are mean ± 
standard error (n = 3). 
	
	
	
	
	
	
	
	 78	
	
	
	
Figure 2.7. Effect of increased Ca2+ concentration on FX activation by memTF/FVIIa in 
solution. In each case, the initial rates of FX activation by memTF/FVIIa complexes in detergent 
solution (0.1% Triton X-100) using 1.85 mM Ca2+ were normalized to the rates observed with 
the same version of memTF (mutant or WT) at 1.25 mM Ca2+. The rates of FX activation 
supported by WT and most memTF mutants were increased approximately 1.3-fold upon 
increasing the Ca2+ concentration from 1.25 to 1.85 mM. However, the rates of FX activation 
supported by two TF mutants (K159A, p = 0.018; and K165A, p = 0.029) were significantly 
decreased upon increasing the Ca2+ concentration (asterisks). Data are mean ± standard error (n ≥ 
3), with statistical significance determined using Student’s t-test. 
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Figure 2.8. TF sequence alignment of the region of interest across selected mammals and birds. 
BLAST search was performed using human TF as the standard (with the amino acid numbering 
also representative of human TF). Highlighted in blue (164-166, 185) were residues most 
important for Mg2+ recognition. Residues in green (157, 159, 163, 180) were intermediate in 
their importance towards recognizing Mg2+. Mutations of residues in red resulted in no 
identifiable defect in Mg2+ response. We note that the TF residues most important for Mg2+ 
recognition are all highly conserved. 
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Table 2.2: Kd Values for TF/FVIIa under Varying Divalent Metal Ion Conditions 
 Kd (nM)a  
TF (WT or mutant) 1.85 mM Ca2+ 1.25 mM Ca
2+ + 
0.6 mM Mg2+ Ratio
b 
WT 0.39 ± 0.1 0.58 ± 0.1 1.48 ± 0.4 
Y157A 0.13 ± 0.05 0.23 ± 0.02 1.87 ± 0.7 
S163A 0.70 ± 0.3 0.57 ± 0.1 0.81 ± 0.4 
G164A 1.03 ± 0.3 1.26 ± 0.06 1.22 ± 0.3 
K165A 0.66 ± 0.3 0.94 ± 0.5 1.42 ± 1 
K166A 0.44 ± 0.08 0.47 ± 0.04 1.07 ± 0.2 
D180A 1.07 ± 0.3 0.86 ± 0.2 0.80 ± 0.3 
Y185A 0.43 ± 0.1 0.49 ± 0.1 1.15 ± 0.4 
aValues for Kd are mean ± standard error (n ≥ 3). bRatios are mean Kd at 1.25 mM Ca2+ + 0.6 mM 
Mg2+ divided by mean Kd at 1.85 mM Ca2+ (± standard error). 
 
The Kd values for FVIIa binding to TF in Table 2.2 were determined using memTF in solution 
(with 0.1% Triton X-100), under conditions of equal total divalent metal ion concentration with 
either no Mg2+ (1.85 mM Ca2+) or with physiologic concentrations of Mg2+ and Ca2+ (1.25 mM 
Ca2+ + 0.6 mM Mg2+). 
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Figure 3.1. Ability of DNA, RNA and polyP to initiate clotting via the contact pathway. 
Varying concentrations of DNA, RNA, or polyP were incubated with pooled normal plasma in 
microplate wells for 3 minutes at 37°C, after which CaCl2 was added and clotting was detected. 
Shortening of the clot time is expressed as percent of the clot time with buffer alone. (See 
supplemental Figure S2 for the distribution of clot times in the absence of activator.) (A) 
Clotting observed with polyP, cell-derived nucleic acids, or lambda DNA: long-chain polyP (), 
medium-chain polyP (n), short-chain polyP (u), HEK 293 cell DNA isolated with DNeasy 
Blood & Tissue kit (q), HEK 293 cell RNA isolated with RNeasy Midi kit (r), or lambda 
DNA ( ¢). (B) Clotting observed with synthetic RNA homopolymers: polyG (s), polyI (¯), 
polyA (£), or polyC (). Data are mean ± SEM (n ≥ 3). 
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Figure 3.2. Ability of DNA, RNA and polyP to abrogate the anticoagulant activity of TFPI. 
The indicated polymers and 200 ng/mL TFPI were added to pooled normal plasma at 37°C, 
after which clotting was initiated by addition of factor Xa and CaCl2 and detected using a 
coagulometer. The clot time of plasma with TFPI but no added polymer was defined as 100% 
(q+TFPI); for comparison, clotting of plasma without added TFPI or polymer is also plotted 
(q-TFPI). Polymers added were: short-chain polyP (u), HEK 293 cell DNA isolated with 
DNeasy Blood & Tissue kit (q), HEK 293 cell RNA isolated with RNeasy Midi kit (r), 
lambda DNA (¢), polyG (s), polyI (¯), polyA (£), or polyC (). Data are mean ± SEM 
(n ≥ 3). 
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Figure 3.3. Effect of enzyme digestion on the procoagulant activity of polyP, cell-derived DNA 
and lambda DNA. HEK 293 cell DNA isolated with DNeasy Blood & Tissue kit (50 µg/mL), 
lambda DNA (20 µg/mL), or long-chain polyP (2 µg/mL) was incubated with pooled normal 
plasma in microplate wells for 3 minutes at 37°C, after which CaCl2 was added and clotting was 
detected. Shortening of the clot time is expressed as percent of the clot time with buffer alone. 
Effects of enzymatic predigestion of DNA or polyP for 30 minutes at 37°C on clotting, using: 
no enzyme (black bars), 700 U/mL Benzonase (grey), or 300 U/mL calf intestinal alkaline 
phosphatase (CIAP, white). Statistical significance was assessed using a two-tailed t-test against 
the no enzyme sample. *P < 0.05; **P < 0.01; ***P < 0.001. Data are mean ± SEM (n ≥ 3). 
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Figure 3.4. Ability of mixtures of DNA and polyP to initiate clotting via the contact pathway. 
Plasma clotting was evaluated in a microplate-based assay in which the contact pathway was 
triggered by DNA plus polyP. Activators were incubated with pooled normal plasma in 
microplate wells for 3 minutes at 37°C, after which CaCl2 was added and clotting was detected. 
Shortening of the clot time is expressed as percent of the clot time with buffer alone. (A) 
Clotting observed with varying concentrations of polyP alone or with a constant concentration of 
lambda DNA: short-chain polyP alone (u) or with 20 µg/mL lambda DNA (¯); medium-
chain polyP alone (n) or with 20 µg/mL lambda DNA (£). (B) Clotting observed with varying 
concentrations of a combination of medium-chain polyP and lambda DNA at a fixed mass ratio 
of 1:100 (£). PolyP concentrations are given on the upper x-axis and DNA concentrations on 
the lower x-axis. For comparison, clotting observed with medium-chain polyP alone (n), HEK 
293 cell DNA alone (isolated with DNeasy Blood & Tissue kit) (s), and lambda DNA alone 
(p) are also plotted using the corresponding x-axes. Data are mean ± SEM (n ≥ 3).	
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Figure 3.5. Recovery of nucleic acids and polyP with commercial nucleic acid purification kits. 
Known quantities of lambda DNA (DNA, gray bars), polyG (RNA, white bars) and/or long-
chain polyP (black bars) were processed for nucleic acid purification using Qiaquick, DNeasy, or 
TRIzol kits, following the manufacturer’s instructions. Recovered nucleic acids or polyP were 
quantified as described in Materials and Methods and plotted as percent of the input amount in 
each experiment. The 3 samples were: (A) nucleic acid alone, consisting of 5 µg of either lambda 
DNA or polyG (RNA); (B) 5 µg polyP alone; or (C) a mixture of 5 µg polyP plus 5 µg of either 
lambda DNA or polyG (RNA). Experiments with the Qiaquick kit employed 2.5 µg of polyP 
and/or nucleic acid. Data are mean ± SEM (n ≥ 3). 
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Figure 3.6. Traces of polyP in cell-derived DNA. DNA isolated from HEK 293 cells using the 
DNeasy Blood & Tissue kit was concentrated to 3 mg/mL and resolved by electrophoresis on a 
4-20% polyacrylamide gel. The same gel was stained sequentially, using: (A) DAPI and (B) 
SYBR Green I (after removing DAPI by repeated rinsing). Samples were: 1 kb DNA ladder 
(lane 1); HEK 293 DNA (lane 2); HindIII-digested lambda DNA (lane 3); Benzonase-digested 
HEK 293 DNA (lane 4); and Benzonase-digested, HindIII-digested lambda DNA (lane 5). 
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Figure 3.7. Urea-PAGE of RNA homopolymers and polyP. PolyP preparations and RNA 
homopolymers used in this study were resolved by PAGE using TBE-urea gels (10% 
polyacrylamide). 2 µg of each sample was loaded into the following lanes, with 2M urea in the 
loading buffer: 1, Low MW DNA Ladder; 2, long-chain polyP; 3, medium-chain polyP; 4, 
short-chain polyP; 5, polyI; 6, polyG; 7, polyC; 8, polyA. PolyP and nucleic acids were stained 
for 5 minutes with 0.05% toluidine blue in 5% glycerol/25% methanol, and de-stained overnight 
in 5% glycerol/25% methanol. 
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Figure 3.8. Distribution of clot times in the absence of activator. The clotting times in Figures 1, 
3, and 4 (and in Supplemental Figure S3) were normalized to the clot times in the absence of any 
added activator (polyanion) within each experimental run. Data on observed plasma clotting times 
in the absence of activator are plotted on the left as a box-and-whisker plot (depicting the 
minimum, 25th percentile, median, 75th percentile, and maximum), and shown in detail on the 
right in tabular form. 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Plasma clot times in the absence of any 
added activator 
Number of replicates 54 
Minimum clot time (sec) 218.5 
Maximum clot time (sec) 719.2 
Median clot time (sec) 331.0 
Mean clot time (sec) 366.8 
Standard Deviation (sec) 106.4 
Standard Error (sec) 14.48 
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Figure 3.9. Ability of DNA, RNA and polyP to initiate clotting via the contact pathway, plotted 
on a molar basis. Alternative representation of the data presented in Figure 1, with clot times 
plotted vs. molar concentration of polyP (in terms of phosphate monomer) or molar 
concentration of DNA (also in terms of phosphate, which is identical to the molar concentration 
of nucleotides). Varying concentrations of DNA, RNA, or polyP were incubated with pooled 
normal plasma in microplate wells for 3 minutes at 37°C, after which CaCl2 was added and 
clotting was detected. Shortening of the clot time is expressed as percent of the clot time with 
buffer alone. (A) Clotting observed with polyP, cell-derived nucleic acids, or lambda DNA: 
long-chain polyP (), medium-chain polyP (n), short-chain polyP (u), HEK 293 cell DNA 
isolated with DNeasy Blood & Tissue kit (q), HEK 293 cell RNA isolated with RNeasy Midi 
kit (r), or lambda DNA ( ¢). (B) Clotting observed with synthetic RNA homopolymers: 
polyG (s), polyI (¯), polyA (£), or polyC (). Data are mean ± SEM (n ≥ 3). 
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Figure 3.10. CIAP and Benzonase digestion of DNA and polyP.  Lambda DNA-HindIII digest 
and long-chain polyP were incubated with CIAP, Benzonase, or no enzyme, then resolved on 4-
20% polyacrylamide gels. PolyP and DNA were visualized via DAPI staining, which fluoresces 
in the presence of DNA, but which rapidly photobleaches in the presence of polyP (negative 
staining). (A) Lambda DNA: Lanes 1 and 10, 100 bp DNA ladder; lanes 2 and 3, Lambda 
DNA-Hind III digest, further digested with CIAP; lanes 4 and 5, Lambda DNA-Hind III 
digest, further digested with Benzonase; lanes 6 and 7, Lambda DNA-Hind III digest, further 
digested with PPX1; lanes 8 and 9, no enzyme. (B) Long-chain polyP (mode = 1125). Lanes 1 
and 10, 100 bp DNA ladder; lanes 2 and 3, polyP incubated in buffer without enzyme; lanes 4 
and 5, polyP after PPX1 digestion; lanes 6 and 7, polyP after Benzonase digestion; lanes 8 and 9, 
polyP after CIAP digestion. 
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Table 3.1. Nucleic acid purification kits used in studies of the procoagulant 
activity of DNA and RNA 
 
Kit Name Manufacturer Type/Principle Used By 
Qiaquick PCR 
Purification  
Qiagen Silica  Modified protocol used by 
Nickel et al. (2015)221* 
 
DNeasy Blood 
and Tissue 
Qiagen Silica Vu et al. (2015)277 
Bhagirath et al. (2015)225 
QIAamp Blood Qiagen Silica Gould et al. (2014)175 
Gould et al. (2015)177 
Swystun et al. (2011)278 
 
RNeasy Mini  Qiagen Silica Kannemeier et al. (2007)166 
 
 
RNeasy Plus 
Mini 
Qiagen Silica Vu et al. (2015)277 
TRIzol Invitrogen Guanidinium isothiocyanate 
and acidic phenol/chloroform 
extraction 
Kannemeier et al. (2007)166 
 
   *Utilized for the purification of 
polyP 
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Figure 4.1. Schematic overview of the contact pathway. Specific proteolytic activation events 
that were examined in this study are numbered. PPK can be activated by PK (1) or FXIIa (2). 
FXII can be activated by FXIIa (3) or PK (4). FXI can be activated by FXIa (5), FXIIa (6), or 
thrombin (7). The common pathway represents the bulk of the clotting cascade, from factor IX 
activation through thrombin generation.  
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Figure 4.2. FXI(a) interactions with RNA and polyP. (A) Ability of 50 μM solution-phase polyP 
or RNA homopolymers to compete with immobilized biotin-polyP for binding to 50 nM FXIa 
in the presence (black bars) or absence (white bars) of 50 nM HK. Bound FXIa in microplate 
wells was normalized to the amount bound in the absence of any competing polyanion (“None”). 
(B) Second-order rate constants for FXI autoactivation in the absence of HK. 40 nM FXI was 
incubated with 100 pM FXIa and either 2.5 μM polyP, 1.25 μM polyG, 1.25 μM polyI or no 
polymer (“Vehicle”). (C) Second-order rate constants for polyP- and polyI-mediated FXI 
autoactivation. 40 nM FXI was incubated with 100 pM FXIa and either 2.5 to 10 μM polyP or 
1.25 μM polyI, in the presence (black bars) or absence (white bars) of 40 nM HK. (D) FXI 
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Figure 4.2 (cont.) activation by thrombin, plotted as initial rates of FXI activation divided by the 
thrombin concentration. 40 nM FXI with (black bars) or without (white bars) 40 nM HK was 
incubated with 15 nM thrombin in the presence of either 15 μM polyP, 6 μM polyG, 10 μM 
polyI, or no polymer. (E) FXI activation by FXIIa in the presence (dotted lines), or absence 
(solid lines) of 40 nM HK. 40 nM FXI was incubated with 5 nM FXII plus either 1.25 μM 
polyP (green ¢), 1.25 μM polyI (purple ), 1.25 μM polyG (blue ¿), or no polymer (red ▲). 
(F) Data in panel F is the same progress curves of FXIa generation with the exception of polyP 
(green ¢), which is 2.5 μM in panel F. Panel E represents the first 10 min, and panel F 
represents the full 30-min time course. Data in all panels are mean ± standard error (n ≥ 3). 
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Figure 4.3. FXII(a) interactions with RNA and polyP. (A) Ability of 50 μM solution-phase 
polyP or RNA homopolymers to compete with immobilized biotin-polyP for binding to 50 nM 
FXIIa in the presence (black bars) or absence (white bars) of 50 nM HK. Bound FXIIa in 
microplate wells was normalized to the amount bound in the absence of any competing 
polyanion (“None”). (B) Discontinuous assay of FXII autoactivation (using 200nM FXII) in the 
presence (solid lines) or absence (dotted lines) of 200 nM HK and 10 μM of either polyP (green 
q), polyG (purple ¢), or polyI (blue ). FXIIa activity (rate of chromogenic substrate 
hydrolysis) is plotted as mOD/min versus time. (C) Continuous assay of FXII autoactivation 
(using 200 nM FXII) in the presence (solid lines) or absence (dotted lines) of 200 nM HK and 
either 100 μM polyP (green), 5 μM polyG (purple), or 5 μM polyI (blue). FXIIa activity is 
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Figure 4.3 (cont.) plotted as the A405 generation versus time. (D) Second-order rate constants in 
the continuous activation assay for 5 μM polyG-, 5 μM polyI-, or no polymer (“Vehicle”) 
mediated autoactivation of FXII, in the presence or absence of HK. Initial concentrations of 
FXII and HK were 200 nM. Rates were derived using the continuous autoactivation assay as 
shown in Figure 3C. (E) Initial rates of activation of 200 nM FXII by 1 nM PK in the 
discontinuous assay in the presence (black) or absence (white) of 200 nM HK and either 20 μM 
polyP, 10 μM polyG, 10 μM polyI, or no polymer (“Vehicle”). Data in all panels are mean ± 
standard error (n ≥ 3), except for the vehicle control in panel D (n = 2).  
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Figure 4.4. (P)PK interactions with RNA and polyP. (A) Ability of 50 μM solution-phase polyP 
or RNA homopolymers to compete with immobilized biotin-polyP for binding to 50 nM PK in 
the presence of 50 nM HK. Bound PK in microplate wells was normalized to the amount bound 
in the absence of any competing polyanion (“None”). (PK did not bind appreciably to polyP in 
the absence of HK.) (B) Raw data from continuous PPK autoactivation assays, in triplicate. 
Autoactivation of 100 nM PPK plus 100 nM HK was examined in the presence of either 10 μM 
polyP (green), 5 μM polyG (purple), or 5 μM polyI (blue). (No appreciable PK activity 
developed in the absence of HK, even in the presence of polyP, polyG or polyI.) (C) Second-
order rate constants from the continuous assay for PPK autoactivation by 10 μM polyP, 2.5 μM 
polyG, 2.5 μM polyI or no polymer (“Vehicle”) in the presence of equimolar HK. (D) Initial 
rates of activation of 50 nM PPK by 250 pM FXIIa in a discontinuous assay in the presence 
(black) or absence (white) of 50 nM HK and either 10 μM polyP, 2.5 μM polyG, 2.5 μM polyI, 
or no polymer. Data in all panels are mean ± standard error (n ≥ 3). 
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Figure 4.5. Qualitative summary of our findings on the effects of polyP or RNA (in the presence 
or absence of HK) on the various activation reactions of the contact pathway. The number of 
plus signs (+) indicates the rate of the reaction relative to the maximum rate supported in the 
presence of HK, while a minus sign (−) indicates that the reaction was not detected under that 
condition. Approximately, reaction rates above the 80th percentile received (+++), above the 33rd 
percentile received (++), and below the 33rd percentile received (+). The intensities of the green or 
red colors correspond qualitatively to the change in rate upon addition of HK (red = rate 
decreased; green = rate increased; white = no effect). Reaction numbers in the first column 
correspond to the reaction numbers depicted in Figure 1. 
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